Peter Jüni

Peter Jüni

University of Toronto

H-index: 158

North America-Canada

About Peter Jüni

Peter Jüni, With an exceptional h-index of 158 and a recent h-index of 114 (since 2020), a distinguished researcher at University of Toronto, specializes in the field of Clinical Epidemiology, Epidemiology, Cardiology, Clinical Trials, Meta-Analysis.

Peter Jüni Information

University

University of Toronto

Position

Director AHRC St. Michael's Hospital and Professor of Medicine

Citations(all)

250578

Citations(since 2020)

175800

Cited By

129153

hIndex(all)

158

hIndex(since 2020)

114

i10Index(all)

515

i10Index(since 2020)

438

Email

University Profile Page

University of Toronto

Peter Jüni Skills & Research Interests

Clinical Epidemiology

Epidemiology

Cardiology

Clinical Trials

Meta-Analysis

Top articles of Peter Jüni

The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials

Authors

Leonardo Buttice,Maryam Ghani,Janahan Suthakar,Sathyan Gnanalingham,Elliott Carande,Brett WC Kennedy,Alex Pitcher,James HP Gamble,Mahmood Ahmad,Andrew Lewis,Peter Jüni,Oliver J Rider,Jeffrey W Stephens,Jonathan JH Bray

Journal

Diabetes, Obesity and Metabolism

Published Date

2024/4/11

Aims To conduct a meta‐analysis of randomized controlled trials (RCTs) to assess the effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on inflammatory biomarkers. Methods Medline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity. Results Thirty‐eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow‐up of 16 (12–24) weeks. Meta‐analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin‐6, tumour necrosis factor receptor‐1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model …

Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of …

Authors

Antonio Landi,Victor Aboyans,Dominick J Angiolillo,Dan Atar,Davide Capodanno,Keith AA Fox,Sigrun Halvorsen,Stefan James,Peter Jüni,Sergio Leonardi,Roxana Mehran,Gilles Montalescot,Eliano Pio Navarese,Josef Niebauer,Angelo Oliva,Raffaele Piccolo,Susanna Price,Robert F Storey,Heinz Völler,Pascal Vranckx,Stephan Windecker,Marco Valgimigli

Journal

European Heart Journal: Acute Cardiovascular Care

Published Date

2024/1

Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring a critical assessment of patient comorbidities, clinical presentation, revascularization modality, and/or optimization of medical treatment. The 2023 European Society of Cardiology (ESC) guidelines for the management of patients with ACS encompassing both patients with and without ST segment elevation ACS have been recently published. Shortly before, a European expert consensus task force produced guidance for clinicians on the management of antithrombotic therapy in patients with ACS as well as chronic coronary syndrome. The scope of this manuscript is to provide a critical appraisal of differences and similarities between the European consensus paper and the latest …

Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis: a network meta-analysis of large randomized trials

Authors

Tiago V Pereira,Pakeezah Sadaat,Pavlos Bobos,Samir Iskander,Nicolas S Bodmer,Martina Rudnicki,Henry D Kiyomoto,Thais Montezuma,Matheus O Almeida,Rishi Bansal,Pai-Shan Cheng,Alex J Sutton,Peter Tugwell,Gillian Hawker,Peter Jüni,Bruno R da Costa

Journal

Osteoarthritis and Cartilage

Published Date

2024/4/1

Purpose (the aim of the study): To identify the most effective and safest intra-articular interventions to reduce pain and improve physical function in patients with knee or hip OA.Methods: Data Sources: Electronic searches in the Cochrane Controlled Clinical Trial Register, regulatory agency websites, and ClinicalTrials. gov were performed (database inception to October, 2023).Study Selection: Randomized trials reported in English with≥ 100 patients per group that compared any intra-articular intervention to another intra-articular treatment, placebo or standard care.Main Outcomes and Measures: The prespecified primary outcome was pain intensity. We also assessed physical function and safety outcomes. Both pain intensity and physical function were evaluated at multiple time points: 2, 6, 12, 24 and 52 weeks after randomization.Data Extraction and Synthesis: Data were independently extracted by two …

Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Authors

Antonio Landi,Mirvat Alasnag,Dik Heg,Enrico Frigoli,Fazila Tun Nesa Malik,Ivan Gomez-Blazquez,Suzanne Pourbaix,Alaide Chieffo,Christian Spaulding,Fermin Sainz,Helen Routledge,Giuseppe Andò,Luca Testa,Alessandro Sciahbasi,Hussain Contractor,Nigel Jepson,Juan Mieres,Syed Saqib Imran,Husam Noor,Pieter C Smits,Marco Valgimigli,Peter C Smits,GA Van Es,GBWE Vos,E Spitzer,Pascal Vrancks,Bernard Chevalier,Yukio Ozaki,Marie-Claude Morice,Stephan Windecker,Yoshinobu Onuma,Andrè Frenk,Peter C Jüni,Jan Tijssen,D Paunovic,Mullasari S Ajit,Jozef Bartunek,Antonio Colombo,David Hildick-Smith,Andrés Iñiguez,Felix Mahfoud,Ran Kornowski,Maciej Lesiak,Paul JL Ong,Alfredo E Rodriguez,Marco Roffi,Carl Schultz,Goran Stankovic,Pim Tonino,Aris Moschovitis,Peep Laanmets,Michael Donahue,M Bertrand,Stuart Pocock,Philip Urban,Sergio Leonardi,Claude Hanet,Renato Lopes,Eùgene P McFadden,Peter Radke,Risto O Roine,Boudijn Ladan,Laura van der Waal,Yvonne Engelbrecht,Fred Paddenburg,Ben Ren,Ingrid de Zwart,Liliane Elshout,Judith Jonk,Tessa Rademaker-Havinga,Ria van Vliet,Phani Krishna Kondamudi,Laure Morsiani,Ute Windhövel,Anita van der Wal,Chantal Bakker,Kazuhiro Minagawa,Fernando Cura,Carlos Fernandez-Pereira,Astin Lee,Robert Whitbourn,Owen Christopher Raffel,Kurt Huber,Franz Weidinger,Jessa Ziekenhuis,Imelda Ziekenhuis,Willem Dewilde,Adel Aminian,Emanuele Aalst,Panagiotis Xaplanteris,Vasil Velchev,Dimitar Karageorgiev,Hristo Mateev,Valeri Gelev,Petr Kala,Martin Mates,Henning Kelbæk,Thomas Hovasse,Laurent Delorme,Thomas Cuisset,Loïc Belle,Farzin Beygui,Christophe Piot,Jean François Morelle,Rene Koning,Mathieu Valla,Philippe Brunel,Guillaume Cayla,Emmanuel Teiger,Gilles Montalescot,Phillipe Guyon,Pyxaras Stylianos,Bela Merkely,Imre Ungi,Rajpal K Abhaichand,Atul Damodar Abhyankar,Gunasekaran Sengottuvelu,Halabi Majdi,Ariel Roguin,Yair Feld,Chaim Lotan,Stefano Garducci,Bernhard Reimers,Gennaro Sardella,Antonio Milan,Corrado Tamburino,Maurizio Di Biasi,Paolo Calabro,Gianluigi Minervini,Bruno Loi,Franco Fabbiocchi,Jacopo Oreglia,Paolo Sganzerla,Kenji Ando,Yoshiharu Higuchi,Mamoru Nanasato,Yuki Ishibashi,Hitoshi Matsuo,Ruka Yoshida,Kiyokazu Shimizu,Haruo Kamiya,Nobuyuki Komiyama,Tetsuya Amano,Toyoaki Murohara,Seiji Yamazaki,Sasko Kedev,Jakub Podolec,Krzysztof Reszuch,Adrian Wlodarczak,Dariusz Dudek

Journal

JAMA cardiology

Published Date

2024/1/1

ImportanceAbbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).ObjectivesTo evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR.Design, Setting, and PatientsThis prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019. A total of 4579 patients with HBR were randomized at 1 month after PCI to abbreviated or standard DAPT. Data were analyzed from July 1 to October 31 …

Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial

Authors

Oriol Manuel,Mirjam Laager,Cédric Hirzel,Dionysios Neofytos,Laura N Walti,Gideon Hoenger,Isabelle Binet,Aurelia Schnyder,Susanne Stampf,Michael Koller,Matteo Mombelli,Min Jeong Kim,Matthias Hoffmann,Katrin Koenig,Christoph Hess,Anne-Valérie Burgener,Pietro E Cippà,Kerstin Hübel,Thomas F Mueller,Daniel Sidler,Suzan Dahdal,Franziska Suter-Riniker,Jean Villard,Andrea Zbinden,Giuseppe Pantaleo,Nasser Semmo,Karine Hadaya,Natalia Enríquez,Pascal R Meylan,Marc Froissart,Dela Golshayan,Thomas Fehr,Uyen Huynh-Do,Manuel Pascual,Christian Van Delden,Hans H Hirsch,Peter Jüni,Nicolas J Mueller

Journal

Clinical Infectious Diseases

Published Date

2024/2/15

Background The use of assays detecting cytomegalovirus (CMV)–specific T cell–mediated immunity may individualize the duration of antiviral prophylaxis after transplantation. Methods In this randomized trial, kidney and liver transplant recipients from 6 centers in Switzerland were enrolled if they were CMV-seronegative with seropositive donors or CMV-seropositive receiving antithymocyte globulins. Patients were randomized to a duration of antiviral prophylaxis based on immune monitoring (intervention) or a fixed duration (control). Patients in the control group were planned to receive 180 days (CMV-seronegative) or 90 days (CMV-seropositive) of valganciclovir. Patients were assessed monthly with a CMV ELISpot assay (T-Track CMV); prophylaxis in the intervention group was stopped if the assay was positive. The co-primary outcomes were the proportion of patients with …

2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of …

Authors

Robert A Byrne,Xavier Rossello,JJ Coughlan,Emanuele Barbato,Colin Berry,Alaide Chieffo,Marc J Claeys,Gheorghe-Andrei Dan,Marc R Dweck,Mary Galbraith,Martine Gilard,Lynne Hinterbuchner,Ewa A Jankowska,Peter Jüni,Takeshi Kimura,Vijay Kunadian,Margret Leosdottir,Roberto Lorusso,Roberto FE Pedretti,Angelos G Rigopoulos,Maria Rubini Gimenez,Holger Thiele,Pascal Vranckx,Sven Wassmann,Nanette Kass Wenger,Borja Ibanez

Published Date

2024/1

The major aspects of the management of patients with acute coronary syndromes described in this European Society of Cardiology (ESC) Guideline are summarized in Figure 1.

Swiss trial of decompressive craniectomy versus best medical treatment of spontaneous supratentorial intracerebral haemorrhage (SWITCH): an international, multicentre …

Authors

Urs Fischer,Christian Fung,Seraina Beyeler,Lukas Bütikofer,Werner Z’Graggen,Florian Ringel,Jan Gralla,Karl Schaller,Nikolaus Plesnila,Daniel Strbian,Marcel Arnold,Werner Hacke,Peter Jüni,Alexander David Mendelow,Christian Stapf,Rustam Al-Shahi Salman,Jenny Bressan,Stefanie Lerch,Claudio LA Bassetti,Heinrich P Mattle,Andreas Raabe,Jürgen Beck

Journal

European stroke journal

Published Date

2024/2/12

RationaleDecompressive craniectomy (DC) is beneficial in people with malignant middle cerebral artery infarction. Whether DC improves outcome in spontaneous intracerebral haemorrhage (ICH) is unknown.AimTo determine whether DC without haematoma evacuation plus best medical treatment (BMT) in people with ICH decreases the risk of death or dependence at 6 months compared to BMT alone.Methods and designSWITCH is an international, multicentre, randomised (1:1), two-arm, open-label, assessor-blinded trial. Key inclusion criteria are age ⩽75 years, stroke due to basal ganglia or thalamic ICH that may extend into cerebral lobes, ventricles or subarachnoid space, Glasgow coma scale of 8–13, NIHSS score of 10–30 and ICH volume of 30–100 mL. Randomisation must be performed <66 h after onset and DC <6 h after randomisation. Both groups will receive BMT. Participants randomised to the …

Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through …

Authors

Elmir Omerovic,Mark Petrie,Björn Redfors,Stephen Fremes,Gavin Murphy,Guillaume Marquis-Gravel,Alexandra Lansky,Eric Velazquez,Divaka Perera,Christopher Reid,Julian Smith,Peter van der Meer,Eric Lipsic,Peter Juni,John McMurray,Johann Bauersachs,Lars Køber,Jean L Rouleau,Torsten Doenst

Journal

Trials

Published Date

2024/1/23

In an era focused on value-based healthcare, the quality of healthcare and resource allocation should be underpinned by empirical evidence. Pragmatic clinical trials (pRCTs) are essential in this endeavor, providing randomized controlled trial (RCT) insights that encapsulate real-world effects of interventions. The rising popularity of pRCTs can be attributed to their ability to mirror real-world practices, accommodate larger sample sizes, and provide cost advantages over traditional RCTs. By harmonizing efficacy with effectiveness, pRCTs assist decision-makers in prioritizing interventions that have a substantial public health impact and align with the tenets of value-based health care. An international network for pRCT provides several advantages, including larger and diverse patient populations, access to a broader range of healthcare settings, sharing knowledge and expertise, and overcoming ethical and …

Limiting dynamic driving pressure in patients requiring mechanical ventilation

Authors

Martin Urner,Peter Jüni,L Paloma Rojas-Saunero,Bettina Hansen,Laurent J Brochard,Niall D Ferguson,Eddy Fan

Journal

Critical care medicine

Published Date

2023/7/1

Objectives:Previous studies reported an association between higher driving pressure (∆ P) and increased mortality for different groups of mechanically ventilated patients. However, it remained unclear if sustained intervention on∆ P, in addition to traditional lung-protective ventilation, improves outcomes. We investigated if ventilation strategies limiting daily static or dynamic∆ P reduce mortality compared with usual care in adult patients requiring greater than or equal to 24 hours of mechanical ventilation.Design:For this comparative effectiveness study, we emulated pragmatic clinical trials using data from the Toronto Intensive Care Observational Registry recorded between April 2014 and August 2021. The per-protocol effect of the interventions was estimated using the parametric g-formula, a method that controls for baseline and time-varying confounding, as well as for competing events in the analysis of …

Comparative Effectiveness Of Exercise Modalities In Patients With Knee And Hip Osteoarthritis: A Network Meta-Analysis

Authors

P Bobos,T Pereira,P Sadaat,N Bodmer,S Iskander,H Kiyomoto,T Montezuma,M Almeida,L King,G Hawker,P Juni,B da Costa

Journal

Osteoarthritis and Cartilage

Published Date

2023/3/1

Purpose: To assess the effectiveness of different exercise modalities for knee and hip osteoarthritis pain and physical function in large, randomized trials.Methods: We conducted a systematic review with network and pairwise meta-analysis. We searched CENTRAL, MEDLINE, Embase and ClinicalTrials. gov from their inception until June 2022. We included randomized trials with≥ 100 patients per group, evaluating any exercise interventions (land or water-based) such as strengthening, flexibility or aerobic alone or a combination of programmes for the treatment of osteoarthritis. The prespecified primary outcome was pain intensity at 12-weeks and secondary was physical function. Outcomes were extracted at 6-, 12-, 24-and 52-weeks of follow-up. Two reviewers independently extracted outcome data and evaluated the risk of bias of included trials. We used Bayesian random-effects models for network and …

Impact of post-PCI FFR stratified by coronary artery

Authors

Carlos Collet,Nils P Johnson,Takuya Mizukami,William F Fearon,Colin Berry,Jeroen Sonck,Damien Collison,Bon-Kwon Koo,Nicolas Meneveau,Shiv Kumar Agarwal,Barry Uretsky,Abdul Hakeem,Joon-Hyung Doh,Bruno R Da Costa,Keith G Oldroyd,Jonathon A Leipsic,Umberto Morbiducci,Charles Taylor,Brian Ko,Pim AL Tonino,Divaka Perera,Toshiro Shinke,Claudio Chiastra,Andrei C Sposito,Antonio Maria Leone,Olivier Muller,Stephane Fournier,Hitoshi Matsuo,Julien Adjedj,Nicolas Amabile,Zsolt Piróth,Fernando Alfonso,Fernando Rivero,Jung-Min Ahn,Gabor G Toth,Abdul Ihdayhid,Nick EJ West,Tetsuya Amano,Eric Wyffels,Daniel Munhoz,Marta Belmonte,Hirofumi Ohashi,Koshiro Sakai,Emanuele Gallinoro,Emanuele Barbato,Thomas Engstrøm,Javier Escaned,Ziad A Ali,Morton J Kern,Nico HJ Pijls,Peter Jüni,Bernard De Bruyne

Journal

JACC: Cardiovascular Interventions

Published Date

2023/10/9

Background Low fractional flow reserve (FFR) after percutaneous coronary intervention (PCI) has been associated with adverse clinical outcomes. Hitherto, this assessment has been independent of the epicardial vessel interrogated. Objectives This study sought to assess the predictive capacity of post-PCI FFR for target vessel failure (TVF) stratified by coronary artery. Methods We performed a systematic review and individual patient-level data meta-analysis of randomized clinical trials and observational studies with protocol-recommended post-PCI FFR assessment. The difference in post-PCI FFR between left anterior descending (LAD) and non-LAD arteries was assessed using a random-effect models meta-analysis of mean differences. TVF was defined as a composite of cardiac death, target vessel myocardial infarction, and clinically driven target vessel revascularization. Results Overall, 3,336 vessels (n …

Effect of free medicine distribution on health care costs in Canada over 3 years: a secondary analysis of the CLEAN meds randomized clinical trial

Authors

Nav Persaud,Michael Bedard,Andrew Boozary,Richard H Glazier,Tara Gomes,Stephen W Hwang,Peter Jüni,Michael R Law,Muhammad Mamdani,Braden Manns,Danielle Martin,Steven G Morgan,Paul Oh,Andrew D Pinto,Baiju R Shah,Frank Sullivan,Norman Umali,Kevin E Thorpe,Karen Tu,Fangyun Wu,Andreas Laupacis,Nada Abdel-Malek,Zoe von Aesch,Mouafak Al Hadi,Kelly Anderson,Gordon Arbess,Chris Barnes,Peter Barreca,Seema Bhandarkar,Gary Bloch,Tali Bogler,Ashna Bowry,Donnavan Boyd,Marc Bradford,Anne Browne,Paul Das,MaryBeth Derocher,Katie Dorman,Kathleen Doukas,Esther Ernst,Allison Farber,Hannah Feiner,Amy Freedmon,Kari Fulton,Chantal Gaudreau,Abbas Ghavam-Rassoul,Rajesh Girdhari,Richard Glazier,Irv Gora,Kimberley Gordon,Laurie Green,Samantha Green,Charlie Guiang,Curtis Handford,Maryna Harelnikiva,Candice Holmes,Sue Hranilovic,Karl Igar,Gwen Jansz,Emma Jeavons,Nick Jeeves,Frances Kilbertus,Flo Kim,Tara Kiran,Holly Knowles,Bruce Kwok,Sheila Lakhoo,Margarita Lam-Antoniades,Renata Leong,Fok-Han Leung,Aisha Lofters,Jennifer McCabe,Lora McDougall,Joanne Mellan,Sharon Mintz,Matthew Naccarato,Maya Nader,Kevin O'Connor,James Owen,Judith Peranson,Andrew Pinto,Cristina Pop,Adam Pyle,Julia Rackal,Noor Ramji,Nasreen Ramji,Danyaal Raza,Maurianne Reade,Jane Ridley,Jean Robinson,Katherine Rouleau,Caroline Ruderman,Vanna Schiralli,Lee Schofield,Mary Shamas,Susan Shepherd,Rami Shoucri,Lenka Snajdrova,Andrew Stadnyk,Ann Stewart,Bill Sullivan,Karen Swirsky,Joshua Tepper,Suzanne Turner,Barbara Vari,Priya Vasa,Karim Vellani,Tao Wang,William Watson,Thea Weisdorf,Karen Weiman,Sheila Wijayasinghe,Jean Wilson,Patricia Windrim,CLEAN Meds study team

Journal

JAMA Health Forum

Published Date

2023/5/5

Importance Few interventions are proven to reduce total health care costs, and addressing cost-related nonadherence has the potential to do so. Objective To determine the effect of eliminating out-of-pocket medication fees on total health care costs. Design, Setting, and Participants This secondary analysis of a multicenter randomized clinical trial using a prespecified outcome took place across 9 primary care sites in Ontario, Canada (6 in Toronto and 3 in rural areas), where health care services are generally publicly funded. Adult patients (≥ 18 years old) reporting cost-related nonadherence to medicines in the past 12 months were recruited between June 1, 2016, and April 28, 2017, and followed up until April 28, 2020. Data analysis was completed in 2021. Interventions Access to a comprehensive list of 128 medicines commonly prescribed in ambulatory care with no out-of-pocket costs for 3 years vs usual …

School-based health care: improving academic outcomes for inner-city children—a prospective cohort quasi-experimental study

Authors

Saisujani Rasiah,Peter Jüni,Michael D Sgro,Kevin E Thorpe,Jonathon Maguire,Sloane J Freeman

Journal

Pediatric Research

Published Date

2023/10

BackgroundWe examined whether a school-based health center model improved academic achievement compared to usual care.MethodsThis was a quasi-experimental prospective cohort study. The primary outcome was an academic achievement. In addition, we analyzed sociodemographic characteristics and their relationship to academic achievement, and the wait time for a developmental assessment.ResultsThe differences in change of grades over time (from 2016/2017 to 2018/2019) were small for reading (–0.83, 95% CI –3.48, 1.82, p = 0.51), writing (–1.11, 95% CI –3.25, 1.03, p = 0.28), and math (0.06, 95% CI –3.08, 2.94, p = 0.98). The experimental arm’s average wait time for developmental assessment was 3.4 months.ConclusionIn this small, quasi-experimental prospective cohort study, we did not find evidence that our SBHC model improved academic achievement; however, the wait time at …

Utility of SARS-CoV-2 Genomic Sequencing for Understanding Transmission and School Outbreaks

Authors

Aaron Campigotto,Allison Chris,Julia Orkin,Lynette Lau,Christian Marshall,Ari Bitnun,Sarah A Buchan,Liane MacDonald,Nisha Thampi,Janine McCready,Peter Juni,Rulan S Parekh

Journal

The Pediatric Infectious Disease Journal

Published Date

2023/4/1

Objective:An understanding of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission in schools is important. It is often difficult, using epidemiological information alone, to determine whether cases associated with schools represent multiple introductions from the community or transmission within the school. We describe the use of whole genome sequencing (WGS) in multiple schools to investigate outbreaks of SARS-CoV-2 in the pre-Omicron period.Study Design:School outbreaks were identified for sequencing by local public health units based on multiple cases without known epidemiological links. Cases of SARS-CoV-2 from students and staff from 4 school outbreaks in Ontario underwent WGS and phylogenetic analysis. The epidemiological clinical cohort data and genomic cluster data are described to help further characterize these outbreaks.Results:A total of 132 positive SARS-CoV …

Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease

Authors

Marco Valgimigli,Victor Aboyans,Dominick Angiolillo,Dan Atar,Davide Capodanno,Sigrun Halvorsen,Stefan James,Peter Jüni,Vijay Kunadian,Antonio Landi,Sergio Leonardi,Roxana Mehran,Gilles Montalescot,Eliano Pio Navarese,Josef Niebauer,Angelo Oliva,Raffaele Piccolo,Susanna Price,Robert F Storey,Heinz Völler,Pascal Vranckx,Stephan Windecker,Keith AA Fox

Journal

European Heart Journal-Cardiovascular Pharmacotherapy

Published Date

2023/8

Multiple guidelines and consensus papers have addressed the role of antithrombotic strategies in patients with established coronary artery disease (CAD). Since evidence and terminology continue to evolve, the authors undertook a consensus initiative to guide clinicians to select the optimal antithrombotic regimen for each patient. The aim of this document is to provide an update for clinicians on best antithrombotic strategies in patients with established CAD, classifying each treatment option in relation to the number of antithrombotic drugs irrespective of whether the traditional mechanism of action is expected to mainly inhibit platelets or coagulation cascade. With the aim to reach comprehensiveness of available evidence, we systematically reviewed and performed meta-analyses by means of both direct and indirect comparisons to inform the present consensus document.

Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the …

Authors

Eliano Pio Navarese,Antonio Landi,Angelo Oliva,Raffaele Piccolo,Victor Aboyans,Dominick Angiolillo,Dan Atar,Davide Capodanno,Keith AA Fox,Sigrun Halvorsen,Stefan James,Peter Jüni,Vijay Kunadian,Sergio Leonardi,Roxana Mehran,Gilles Montalescot,Josef Niebauer,Susanna Price,Robert F Storey,Heinz Völler,Pascal Vranckx,Stephan Windecker,Marco Valgimigli

Journal

European Heart Journal-Cardiovascular Pharmacotherapy

Published Date

2023/4

Aims To appraise all available antithrombotic treatments within or after 12 months following coronary revascularization and/or acute coronary syndrome in two network meta-analyses. Methods and results Forty-three (N = 189 261 patients) trials within 12 months and 19 (N = 139 086 patients) trials beyond 12 months were included for efficacy/safety endpoints appraisal. Within 12 months, ticagrelor 90 mg bis in die (b.i.d.) [hazard ratio (HR), 0.66; 95% confidence interval (CI), 0.49–0.88], aspirin and ticagrelor 90 mg (HR, 0.85; 95% CI, 0.76–0.95), or aspirin, clopidogrel and rivaroxaban 2.5 mg b.i.d. (HR, 0.66; 95% CI, 0.51–0.86) were the only treatments associated with lower cardiovascular mortality, compared with aspirin and clopidogrel, without or with greater bleeding risk for the first and the other treatment options, respectively. Beyond 12 months, no strategy lowered mortality …

P22-010-23 Coronary Heart Effectiveness Assessment of the Portfolio Diet in Primary Care (CHEAP) Trial: Protocol for a Randomized Controlled Trial

Authors

Laura Chiavaroli,Meaghan Kavanagh,Andrea Glenn,et al.

Journal

Current Developments in Nutrition

Published Date

2023

Objectives: The period of infancy and early childhood is widely recognized as a critical window for growth and development. Optimal infant and young child feeding practices promote physical health and lay a foundation for cognitive and academic achievement. Despite the well-documented benefits of breastfeeding, current breastfeeding practices lag behind national public health goals, and disparities in breastfeeding practices persist in the United States. Disparities in breastfeeding practices can be seen among families living in a rural county on the US-Mexico border in Arizona, where declines in exclusive breastfeeding occur in early infancy. The objective of this research is to characterize breastfeeding intent and describe the facilitators and barriers to breastfeeding experienced by Latine birthing parents in a rural county on the US-Mexico border of Arizona.Methods: Longitudinal, semi-structured interviews will be conducted with 25 pregnant Latine participants over 18 years of age at three time points: during their third trimester of pregnancy, within three weeks postpartum, and two months postpartum. Trained interviewers, bilingual in Spanish and English, will conduct these semi-structured interviews. Eligible pregnant participants will be recruited from clinics during their third trimester. The first semi-structured interview will include a socio-demographic questionnaire to provide additional background information on each participant. Key informant interviews will also be conducted with 25 healthcare and nutrition professionals, including OB/GYNs, Nurse-Midwives, Pediatricians, Certified Lactation Consultants, WIC staff, and Health Start …

Evaluating Therapies to Prevent Future Stroke in Patients with Patent Foramen Ovale-Related Strokes—The SCOPE Study

Authors

David M Kent,Jeffrey L Saver,Scott E Kasner,Jason Nelson,Andy Y Wang,Raveendhara R Bannuru,John D Carroll,Gilles Chatellier,Geneviève Derumeaux,Anthony J Furlan,Howard C Herrmann,Peter Jüni,Jong S Kim,Benjamin Koethe,Pil Hyung Lee,Benedicte Lefebvre,Heinrich P Mattle,Bernhard Meier,Mark Reisman,Richard W Smalling,Lars Soendergaard,Jae-Kwan Song,Jean-Louis Mas,David E Thaler

Published Date

2023/12/20

BackgroundPatent foramen ovale (PFO)-associated strokes comprise approximately 10% of ischemic strokes in adults aged 18 to 60 years. Despite the overall beneficial effects of closure device placement in patients with a first PFO-associated cerebral ischemic event, the best treatment option for any individual patient encountered in routine clinical practice is often quite unclear.ObjectiveThe objective of this study was to evaluate the heterogeneity of treatment effect of PFO closure on stroke recurrence based on previously developed scoring systems.MethodsIndividual patient data were pooled from 6 randomized clinical trials that compared PFO closure plus medical therapy vs medical therapy alone in patients with PFO-associated stroke, which involved a total of 3740 participants. The trials were conducted worldwide from 2000 to 2017. Comparisons were made between PFO closure plus medical therapy vs medical therapy alone. Subgroup analyses used the Risk of Paradoxical Embolism (RoPE) score (a 10-point score in which higher scores reflect younger age and the absence of vascular risk factors) and the PFO-Associated Stroke Causal Likelihood (PASCAL) algorithm, which combines the RoPE score with high-risk PFO features (either an atrial septal aneurysm or a large shunt) to classify patients into 3 categories of causal relatedness:“unlikely,”“possible,” and “probable.” The main outcome was ischemic stroke.ResultsOver a median follow-up of 57 months (interquartile range, 24-64 months), 121 outcomes occurred in 3740 patients. The annualized incidence of stroke with medical therapy was 1.09%(95% CI, 0.88%-1.36%) and with …

IMPACT OF GEOGRAPHICAL VARIATION BETWEEN EUROPE AND ASIA ON CLINICAL OUTCOMES IN PATIENTS WITH HIGH BLEEDING RISK (HBR) AND BIODEGRADABLE-POLYMER SIROLIMUSELUTING CORONARY …

Authors

Yukio Ozaki,Yoshinobu Onuma,Pieter Smits,Enrico Frigoli,Jan G Tijssen,Peter Juni,pascal vranckx,Marie C Morice,Bernard Chevalier,Stephan Windecker,Pim A Tonino,Marco Roffi,Maciej Lesiak,Felix Mahfoud,Jozef Bartunek,David Hildick-Smith,Antonio Colombo,Goran Stankovic,Andres Iniguez,Carl J Schultz,Ran Kornowski,Paul JL Ong,Dik Heg,Marco Valgimigli

Journal

Journal of the American College of Cardiology

Published Date

2023/3/7

BackgroundIt has been reported that ischemic risk is relatively higher but bleeding risk is vice versa in Europe as compared to those in Asia as known as “East Asian paradox”(Nat Rev Cardiol 2014). It has not yet been established whether such geographical difference between Europe and Asia influences the clinical outcome in patients with high bleeding risk (HBR) and biodegradable-polymer sirolimuseluting coronary stent (Ultimaster TM).MethodsIn the MASTER DAPT study, patients with HBR were randomly assigned to 1-month DAPT (abbreviated therapy) or to at least 3-month DAPT (standard therapy). The three ranked primary outcomes were net adverse clinical events (NACE; a composite of death from any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (MACCE; a composite of death from any cause, myocardial infarction, or stroke), and major or clinically …

Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design

Authors

Francesco Cannata,Giulio Stefanini,Carmelo Carlo-Stella,Mauro Chiarito,Stefano Figliozzi,Laura Novelli,Costanza Lisi,Sara Bombace,Cristina Panico,Francesca Cosco,Francesco Corrado,Giovanna Masci,Rita Mazza,Francesca Ricci,Lorenzo Monti,Giuseppe Ferrante,Armando Santoro,Marco Francone,Bruno R da Costa,Peter Jüni,Gianluigi Condorelli

Journal

Journal of Cardiovascular Medicine

Published Date

2023/7/1

AimsAnthracyclines are the chemotherapeutic agents most frequently associated with cardiotoxicity, while remaining widely used. Different neurohormonal blockers have been tested as a primary prevention strategy to prevent or attenuate the onset of cardiotoxicity, with mixed results. However, prior studies were often limited by a nonblinded design and an assessment of cardiac function based only on echocardiographic imaging. Moreover, on the basis of an improved mechanistic understanding of anthracycline cardiotoxicity mechanisms, new therapeutic strategies have been proposed. Among cardioprotective drugs, nebivolol might be able to prevent the cardiotoxic effects of anthracyclines, through its protective properties towards the myocardium, endothelium, and cardiac mitochondria. This study aims to evaluate the cardioprotective effects of the beta blocker nebivolol in a prospective, placebo-controlled …

Viral Dynamics of the SARS-CoV-2 Omicron Variant in Pediatric Patients: A Prospective Cohort Study

Authors

Michelle Science,Julia Orkin,Bryan Maguire,Ari Bitnun,Laura Bourns,Antoine Corbeil,Jennie Johnstone,Liane Macdonald,Kevin L Schwartz,Cindy Bruce Barrett,Jessica Reinprecht,Alice Heisey,Stephanie Nasso,Peter Jüni,Aaron Campigotto

Journal

Clinical Infectious Diseases

Published Date

2023/12/12

Background There are limited data on the viral dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children. Understanding viral load changes over the course of illness and duration of viral shedding may provide insight into transmission dynamics to inform public health and infection-control decisions. Methods We conducted a prospective cohort study of children aged 18 years and younger with polymerase chain reaction–confirmed SARS-CoV-2 between 1 February 2022 and 14 March 2022. SARS-CoV-2 testing occurred on daily samples for 10 days; a subset of participants completed daily rapid antigen tests (RATs). Viral RNA trajectories were described in relation to symptom onset and resolution. The associations between both time since symptom onset/resolution and non-infectious viral load were evaluated using a Cox proportional hazards …

The COVID-19 pandemic’s impact on long-term care homes: Five lessons learned

Authors

PA Rochon,JM Li,J Johnstone,KA Brown,P Armstrong,P Tanuseputro,R Savage,SS Gill,R Mather,AP Costa,A Mcgeer,SK Sinha,C Gardner,A Perkhun,NS Bodmer,P Jüni

Journal

Science Briefs of the Ontario COVID-19 Science Advisory Table

Published Date

2022/4/28

BackgroundMany inquiries, reports, and legislative reforms have been released in response to multiple waves of the COVID-19 pandemic nationally and provincially. The volume of analysis of the impact of COVID-19 on LTC presents a challenge to decision-makers to identify and prioritize key areas for improvement and action. This brief consolidates recommendations and offers evidence-supported lessons learned and opportunities for change.

Timing of introduction to solid food, growth, and nutrition risk in later childhood

Authors

Curtis J D'Hollander,Charles DG Keown-Stoneman,Catherine S Birken,Deborah L O'Connor,Jonathon L Maguire,Ronald Cohn,Eddy Lau,Andreas Laupacis,Patricia C Parkin,Michael Salter,Peter Szatmari,Shannon Weir,Laura N Anderson,Cornelia M Borkhoff,Christine Kowal,Dalah Mason,Murtala Abdurrahman,Kelly Anderson,Gordon Arbess,Jillian Baker,Tony Barozzino,Sylvie Bergeron,Dimple Bhagat,Gary Bloch,Joey Bonifacio,Ashna Bowry,Caroline Calpin,Douglas Campbell,Sohail Cheema,Elaine Cheng,Brian Chisamore,Evelyn Constantin,Karoon Danayan,Paul Das,Mary Beth Derocher,Anh Do,Kathleen Doukas,Anne Egger,Allison Farber,Amy Freedman,Sloane Freeman,Sharon Gazeley,Charlie Guiang,Dan Ha,Curtis Handford,Laura Hanson,Leah Harrington,Sheila Jacobson,Lukasz Jagiello,Gwen Jansz,Paul Kadar,Florence Kim,Tara Kiran,Holly Knowles,Bruce Kwok,Sheila Lakhoo,Margarita Lam-Antoniades,Denis Leduc,Fok-Han Leung,Alan Li,Patricia Li,Jessica Malach,Roy Male,Vashti Mascoll,Aleks Meret,Elise Mok,Rosemary Moodie,Maya Nader,Katherine Nash,Sharon Naymark,James Owen,Michael Peer,Kifi Pena,Marty Perlmutar,Navindra Persaud,Andrew Pinto,Michelle Porepa,Vikky Qi,Nasreen Ramji,Noor Ramji,Danyaal Raza,Alana Rosenthal,Katherine Rouleau,Caroline Ruderman,Janet Saunderson,Vanna Schiralli,Michael Sgro,Hafiz Shuja,Susan Shepherd,Barbara Smiltnieks,Cinntha Srikanthan,Carolyn Taylor,Stephen Treherne,Suzanne Turner,Fatima Uddin,Meta van den Heuvel,Joanne Vaughan,Thea Weisdorf,Sheila Wijayasinghe,Peter Wong,John Yaremko,Ethel Ying,Elizabeth Young,Michael Zajdman,Farnaz Bazeghi,Vincent Bouchard,Marivic Bustos,Charmaine Camacho,Dharma Dalwadi,Christine Koroshegyi,Tarandeep Malhi,Sharon Thadani,Julia Thompson,Laurie Thompson,Mary Aglipay,Imaan Bayoumi,Sarah Carsley,Katherine Cost,Karen Eny,Theresa Kim,Laura Kinlin,Jessica Omand,Shelley Vanderhout,Leigh Vanderloo,Christopher Allen,Bryan Boodhoo,Olivia Chan,David WH Dai,Judith Hall,Peter Juni,Gerald Lebovic,Karen Pope,Kevin Thorpe,Rita Kandel,Michelle Rodrigues,Hilde Vandenberghe

Journal

The Journal of Pediatrics

Published Date

2022/1/1

ObjectiveTo evaluate the relationship between the timing of infant cereal introduction between 4 and 6 months of age and growth and dietary intake in later childhood.Study designA longitudinal cohort study was conducted among healthy children 0-10 years of age participating in The Applied Research Group for Kids cohort study between June 2008 and August 2019 in Toronto, Canada.ResultsOf 8943 children included, the mean (SD) age of infant cereal introduction was 5.7 (2.1) months. In the primary analysis, children who were introduced to infant cereal at 4 vs 6 months had 0.17 greater body mass index z score (95% CI 0.06-0.28; P = .002) and greater odds of obesity (OR 1.82; 95% CI 1.18-2.80; P = .006) at 10 years of age. In the secondary analysis, children who were introduced to infant cereal at 4 vs 6 months had 0.09 greater height-for-age z score (95% CI 0.04-0.15; P = .002) at 1 year of age, an …

Individual Patient Data Meta-analysis of Drug-eluting Versus Bare-metal Stents for Percutaneous Coronary Intervention in Chronic Versus Acute Coronary Syndromes

Authors

Raffaele Piccolo,Kaare H Bonaa,Orestis Efthimiou,Olivier Varenne,Andrea Baldo,Philip Urban,Christoph Kaiser,Adam de Belder,Pedro A Lemos,Tom Wilsgaard,Jörg Reifart,Expedito E Ribeiro,Patrick WJC Serruys,Robert A Byrne,Jose M de la Torre Hernandez,Giovanni Esposito,William Wijns,Peter Jüni,Stephan Windecker,Marco Valgimigli

Journal

The American Journal of Cardiology

Published Date

2022/11/1

New-generation drug-eluting stents (DES) strongly reduce restenosis and repeat revascularization compared with bare-metal stents (BMS) for percutaneous coronary intervention. There is residual uncertainty as to whether other prognostically relevant outcomes are affected by DES versus BMS concerning initial presentation (chronic coronary syndrome [CCS] vs acute coronary syndrome [ACS]). We performed an individual patient data meta-analysis of randomized trials comparing new-generation DES versus BMS (CRD42017060520). The primary outcome was the composite of cardiac death or myocardial infarction (MI). Outcomes were examined at maximum follow-up and with a 1-year landmark. Risk estimates are expressed as hazard ratio (HR) with 95% confidence interval (CI). A total of 22,319 patients were included across 14 trials; 7,691 patients (34.5%) with CCS and 14,628 patients (65.5%) with ACS …

Cardiovascular meta-analyses: fool’s gold or gold for fools?

Authors

Giuseppe Biondi-Zoccai,Stephan Windecker,Peter Juni,Deepak L Bhatt

Published Date

2022/8/21

Science is by definition iterative and collaborative, with the need for constant reappraisal and external validation, and cardiovascular research is no exception. 1 There has been a veritable democratization of research efforts, and it is a commonplace for the cardiovascular community to witness the conduct and publication of numerous clinical studies with similar scope and goals within a short time frame. The issue in such cases is how to inform ourselves and improve decisionmaking. In other words, which trials should be trusted? All of them? Only the largest ones? Mainly investigator-initiated or governmentfunded trials? Or those of higher methodological quality (Figure 1)?

Use of rapid antigen tests during the omicron wave

Authors

P Jüni,S Baert,A Corbeil,J Johnstone,SN Patel,P Bobos,A Upton,KA Barrett,LL Barrett,NS Bodmer,KB Born

Journal

Science Briefs of the Ontario COVID-19 Science Advisory Table

Published Date

2022/2/10

Declarations of Interest: The declarations of interest of the members of the Ontario COVID-19 Science Advisory Table, its Working Groups, or its partners can be found at https://covid19-sciencetable. ca/. The declarations of interest of external authors can be found under additional resources at https://doi. org/10.47326/ocsat. 2022.03. 56.1. 0About Us: The Ontario COVID-19 Science Advisory Table is a group of scientific experts and health system leaders who evaluate and report on emerging evidence relevant to the COVID-19 pandemic, to inform Ontario’s response. Our mandate is to provide weekly summaries of relevant scientific evidence for the COVID-19 Health Coordination Table of the Province of Ontario, integrating information from existing scientific tables, Ontario’s universities and agencies, and the best global evidence. The Science Table summarizes its findings for the Health Coordination Table and the public in Science Briefs.

Effect of transcutaneous electrical nerve stimulation (TENS) on knee pain and physical function in patients with symptomatic knee osteoarthritis: the ETRELKA randomized …

Authors

Stephan Reichenbach,Peter Jüni,Cesar A Hincapié,Claudio Schneider,DN Meli,Roger Schürch,Sven Streit,Cees Lucas,Christine Mebes,AWS Rutjes,BR da Costa

Journal

Osteoarthritis and cartilage

Published Date

2022/3/1

ObjectiveTo determine the effectiveness of TENS at relieving pain and improving physical function as compared to placebo TENS, and to determine its safety, in patients with knee osteoarthritis.MethodsMulti-centre, parallel, 1:1 randomized, double-blind, placebo-controlled clinical trial conducted in six outpatient clinics in Switzerland. We included 220 participants with knee osteoarthritis recruited between October 15, 2012, and October 15, 2014. Patients were randomized to 3 weeks of treatment with TENS (n = 108) or placebo TENS (n = 112). Our pre-specified primary endpoint was knee pain at the end of 3-weeks treatment assessed with the WOMAC pain subscale. Secondary outcome measures included WOMAC physical function subscale and safety outcomes.ResultsThere was no difference between TENS and placebo TENS in WOMAC pain at the end of treatment (mean difference −0.06; 95%CI -0.41 to 0 …

Community Surveillance of Omicron in Ontario: Wastewater-based Epidemiology Comes of Age.

Authors

Authors presented in alphabetical order,Eric Arts,Stephen Brown,David Bulir,Trevor C Charles,Christopher T DeGroot,Robert Delatolla,Jean-Paul Desaulniers,Elizabeth A Edwards,Meghan Fuzzen,Kimberley Gilbride,Jodi Gilchrist,Lawrence Goodridge,Tyson E Graber,Marc Habash,Peter Jüni,Andrea Kirkwood,James Knockleby,Christopher Kyle,Chrystal Landgraff,Chand Mangat,Douglas G Manuel,R Michael McKay,Edgard Mejia,Aleksandra Mloszewska,Banu Ormeci,Claire Oswald,Sarah Jane Payne,Hui Peng,Shelley Peterson,Art FY Poon,Mark R Servos,Denina Simmons,Jianxian Sun,Minqing Yang,Gustavo Ybazeta

Published Date

2022/3/15

Wastewater-based surveillance of SARS-CoV-2 RNA has been implemented at building, neighbourhood, and city levels throughout the world. Implementation strategies and analysis methods differ, but they all aim to provide rapid and reliable information about community COVID-19 health states. A viable and sustainable SARS-CoV-2 surveillance network must not only provide reliable and timely information about COVID-19 trends, but also provide for scalability as well as accurate detection of known or unknown emerging variants. Emergence of the SARS-CoV-2 variant of concern Omicron in late Fall 2021 presented an excellent opportunity to benchmark individual and aggregated data outputs of the Ontario Wastewater Surveillance Initiative in Canada; this public health-integrated surveillance network monitors wastewaters from over 10 million people across major population centres of the province. We demonstrate that this coordinated approach provides excellent situational awareness, comparing favourably with traditional clinical surveillance measures. Thus, aggregated datasets compiled from multiple wastewater-based surveillance nodes can provide sufficient sensitivity (i.e., early indication of increasing and decreasing incidence of SARS-CoV-2) and specificity (i.e., allele frequency estimation of emerging variants) with which to make informed public health decisions at regional- and state-levels.

Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup …

Authors

Juan F Iglesias,Dik Heg,Marco Roffi,Sophie Degrauwe,David Tüller,Olivier Muller,Miriam Brinkert,Stéphane Cook,Daniel Weilenmann,Christoph Kaiser,Florim Cuculi,Marco Valgimigli,Peter Jüni,Stephan Windecker,Thomas Pilgrim

Journal

Cardiovascular Revascularization Medicine

Published Date

2022/1/1

BackgroundThin-strut biodegradable polymer sirolimus-eluting stents (BP-SES) have been shown to reduce target lesion failure (TLF) at one-year follow-up compared with durable polymer everolimus-eluting stents (DP-EES) among patients with acute coronary syndrome (ACS). The long-term clinical benefits of thin-strut BP-SES over DP-EES in ACS patients after complete degradation of the polymer coating remain uncertain.MethodsWe performed a post-hoc subgroup analysis of ACS patients included into the BIOSCIENCE randomized trial (NCT01443104). The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target-vessel myocardial infarction or clinically indicated target lesion revascularization, at 5 years.ResultsAmong 2119 patients enrolled between March 2012 and May 2013, 1131 (53%) presented with ACS. The 5-year cumulative incidence of TLF was significantly lower in …

Ticagrelor monotherapy or dual antiplatelet therapy after drug‐eluting stent implantation: per‐protocol analysis of the GLOBAL LEADERS trial

Authors

Felice Gragnano,Marcel Zwahlen,Pascal Vranckx,Dik Heg,Kurt Schmidlin,Christian Hamm,Philippe Gabriel Steg,Giuseppe Gargiulo,Eugene P McFadden,Yoshinobu Onuma,Ply Chichareon,Edouard Benit,Helge Möllmann,Luc Janssens,Sergio Leonardi,Aleksander Zurakowski,Alessio Arrivi,Robert Jan Van Geuns,Kurt Huber,Ton Slagboom,Paolo Calabrò,Patrick W Serruys,Peter Jüni,Marco Valgimigli,Stephan Windecker

Journal

Journal of the American Heart Association

Published Date

2022/5/17

Background In the GLOBAL LEADERS trial, ticagrelor monotherapy beyond 1 month compared with standard antiplatelet regimens after coronary stent implantation did not improve outcomes at intention‐to‐treat analysis. Considerable differences in treatment adherence between the experimental and control groups may have affected the intention‐to‐treat results. In this reanalysis of the GLOBAL LEADERS trial, we compared the experimental and control treatment strategies in a per‐protocol analysis of patients who did not deviate from the study protocol. Methods and Results Baseline and postrandomization information were used to classify whether and when patients were deviating from the study protocol. With logistic regressions, we derived time‐varying inverse probabilities of nondeviation from protocol to reconstruct the trial population without protocol deviation. The primary end point was a composite of all …

Arrhythmias and Conduction Disturbances

Authors

Joseph A Ladapo,Mintu P Turakhia,Michael P Ryan,Sarah A Mollenkopf,Matthew R Reynolds,Kadri Murat Gurses,Duygu Kocyigit,Muhammed Ulvi Yalcin,Hande Canpinar,Hikmet Yorgun,Mehmet Levent Sahiner,Ergun Baris Kaya,Mehmet Ali Oto,Necla Ozer,Dicle Guc,Kudret Aytemir

Journal

Coronary Artery Disease

Published Date

2016/5/1

CONTENTS Page 1 CONTENTS THE AMERICAN JOURNAL OF CARDIOLOGYâ VOL. 117, NO. 9 MAY 1, 2016 Coronary Artery Disease Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease ..............................1387 William E. Moody, Erica LS Lin, Matthew Stoodley, David McNulty, Louise E. Thomson, Daniel S. Berman, Nicola C. Edwards, Benjamin Holloway, Charles J. Ferro, Jonathan N. Townend, and Richard P. Steeds, On behalf of the Birmingham Cardio-Renal Group Usefulness of High-Sensitivity Cardiac Troponin T for the Identification of Outlier Patients With Diffuse Coronary Atherosclerosis and Low-Risk Factors.......................................................1397 Marco Magnoni, Serge Masson, Daniele Andreini, Tiziano Moccetti, Maria Grazia Modena, Mauro Canestrari, Sergio Berti, Giancarlo Casolo, Domenico Gabrielli, Paolo Marraccini, Gianluca …

Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis

Authors

Tiago V Pereira,Peter Jüni,Pakeezah Saadat,Dan Xing,Liang Yao,Pavlos Bobos,Arnav Agarwal,Cesar A Hincapié,Bruno R da Costa

Published Date

2022/7/6

Objective To evaluate the effectiveness and safety of viscosupplementation for pain and function in patients with knee osteoarthritis.Design Systematic review and meta-analysis of randomised trials.Data sources Searches were conducted of Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases from inception to 11 September 2021. Unpublished trials were identified from the grey literature and trial registries.Eligibility criteria for study selection Randomised trials comparing viscosupplementation with placebo or no intervention for knee osteoarthritis treatment.Main outcome measures The prespecified primary outcome was pain intensity. Secondary outcomes were function and serious adverse events. Pain and function were analysed as standardised mean differences (SMDs). The prespecified minimal clinically important between group difference was −0.37 SMD. Serious …

Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: meta-analysis of individual …

Authors

Giuseppe Gargiulo,Daniele Giacoppo,Sanjit S Jolly,John Cairns,Michel Le May,Ivo Bernat,Enrico Romagnoli,Sunil V Rao,Maarten AH van Leeuwen,Shamir R Mehta,Olivier F Bertrand,George A Wells,Thomas A Meijers,George CM Siontis,Giovanni Esposito,Stephan Windecker,Peter Juni,Marco Valgimigli,Radial Trialists’ Collaboration

Journal

Circulation

Published Date

2022/11/1

Background In some randomized clinical trials, transradial access (TRA) compared with transfemoral access (TFA) was associated with lower mortality in patients with coronary artery disease undergoing invasive management. We analyzed the effects of TRA versus TFA across multicenter randomized clinical trials and whether these associations are modified by patient or procedural characteristics. Methods We performed an individual patient data meta-analysis of multicenter randomized clinical trials comparing TRA with TFA among patients undergoing coronary angiography with or without percutaneous coronary intervention. The primary outcome was all-cause mortality and the co–primary outcome was major bleeding at 30 days. The primary analysis was conducted by 1-stage mixed-effects models on the basis of the intention-to-treat cohort. The effect of access site on mortality and major bleeding was …

Abstract TMP106: Pooled Analysis Of Five Randomized Trials Comparing Device Closure Of Patent Foramen Ovale After Stroke To Medical Treatment: Impact Of Residual Shunt On …

Authors

David E Thaler,Jeffrey L Saver,Scott Kasner,John Carroll,Anthony J Furlan,Howard C Herrmann,Peter Juni,Jong S Kim,Benjamin Koethe,Pil Hyung Lee,Bénédicte Lefebvre,Jean-Louis Mas,Heinrich P Mattle,Bernhard Meier,Jason Nelson,Mark Reisman,Richard W Smalling,Lars Soendergaard,Jae-kwan Song,David M Kent

Journal

Stroke

Published Date

2022/2

Introduction: Patent foramen ovale (PFO) closure is effective for secondary stroke prevention in well selected patients. After device implantation some patients have residual shunting. There was no impact of incomplete closure on recurrent stroke risk in any of the trials but outcome rates are low with little power to detect an effect. Hypothesis: Patients with residual shunts after PFO closure have more recurrent strokes than those with complete elimination of shunting. Methods: We pooled individual patient data from 5 of 6 randomized clinical trials comparing medical therapy to PFO closure + medical therapy. Residual shunt data were not available for 1 trial. This analysis only includes PFO closure subjects. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated with Cox proportional hazards regression, adjusted for age, sex, coronary disease, diabetes, hypertension, hyperlipidemia, prior stroke/TIA …

Restrictive versus liberal transfusion in patients with diabetes undergoing cardiac surgery: An o pen‐label, randomized, blinded outcome evaluation trial

Authors

Nikhil Mistry,Nadine Shehata,Paula Carmona,Daniel Bolliger,Raymond Hu,François M Carrier,Christella S Alphonsus,Elaine E Tseng,Alistair G Royse,Colin Royse,Daniela Filipescu,Chirag Mehta,Tarit Saha,Juan C Villar,Alexander J Gregory,Duminda N Wijeysundera,Kevin E Thorpe,Peter Jüni,Gregory MT Hare,Dennis T Ko,Subodh Verma,C David Mazer,TRICS Investigators

Journal

Diabetes, Obesity and Metabolism

Published Date

2022/3

Aim To characterize the association between diabetes and transfusion and clinical outcomes in cardiac surgery, and to evaluate whether restrictive transfusion thresholds are harmful in these patients. Materials and Methods The multinational, open‐label, randomized controlled TRICS‐III trial assessed a restrictive transfusion strategy (haemoglobin [Hb] transfusion threshold <75 g/L) compared with a liberal strategy (Hb <95 g/L for operating room or intensive care unit; or <85 g/L for ward) in patients undergoing cardiac surgery on cardiopulmonary bypass with a moderate‐to‐high risk of death (EuroSCORE ≥6). Diabetes status was collected preoperatively. The primary composite outcome was all‐cause death, stroke, myocardial infarction, and new‐onset renal failure requiring dialysis at 6 months. Secondary outcomes included components of the composite outcome at 6 months, and transfusion and clinical …

A web-based health application to translate nutrition therapy for cardiovascular risk reduction in primary care (PortfolioDiet. app): Quality improvement and usability testing …

Authors

Meaghan E Kavanagh,Laura Chiavaroli,Andrea J Glenn,Genevieve Heijmans,Shannan M Grant,Chi-Ming Chow,Robert G Josse,Vasanti S Malik,William Watson,Aisha Lofters,Candice Holmes,Julia Rackal,Kristie Srichaikul,Diana Sherifali,Erna Snelgrove-Clarke,Jacob A Udell,Peter Juni,Gillian L Booth,Michael E Farkouh,Lawrence A Leiter,Cyril WC Kendall,David JA Jenkins,John L Sievenpiper

Journal

JMIR Human Factors

Published Date

2022/4/21

Background: The Portfolio Diet, or Dietary Portfolio, is a therapeutic dietary pattern that combines cholesterol-lowering foods to manage dyslipidemia for the prevention of cardiovascular disease. To translate the Portfolio Diet for primary care, we developed the PortfolioDiet. app as a patient and physician educational and engagement tool for PCs and smartphones. The PortfolioDiet. app is currently being used as an add-on therapy to the standard of care (usual care) for the prevention of cardiovascular disease in primary care. To enhance the adoption of this tool, it is important to ensure that the PortfolioDiet. app meets the needs of its target end users.Objective: The main objective of this project is to undertake user testing to inform modifications to the PortfolioDiet. app as part of ongoing engagement in quality improvement (QI).Methods: We undertook a 2-phase QI project from February 2021 to September 2021. We recruited users by convenience sampling. Users included patients, family physicians, and dietitians, as well as nutrition and medical students. For both phases, users were asked to use the PortfolioDiet. app daily for 7 days. In phase 1, a mixed-form questionnaire was administered to evaluate the users’ perceived acceptability, knowledge acquisition, and engagement with the PortfolioDiet. app. The questionnaire collected both quantitative and qualitative data, including 2 open-ended questions. The responses were used to inform modifications to the PortfolioDiet. app. In phase 2, the System Usability Scale was used to assess the usability of the updated PortfolioDiet. app, with a score higher than 70 being considered acceptable.

Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the …

Authors

Masafumi Ono,Mariusz Tomaniak,Wolfgang Koenig,Ramzi Khamis,Ranil de Silva,Ply Chichareon,Hideyuki Kawashima,Hironori Hara,Chao Gao,Rutao Wang,Kurt Huber,Mathias Vrolix,Pawel Jasionowicz,Joanna J Wykrzykowska,Jan J Piek,Peter Jüni,Christian Hamm,Philippe Gabriel Steg,Stephan Windecker,Yoshinobu Onuma,Robert F Storey,Patrick W Serruys

Journal

European Heart Journal-Cardiovascular Pharmacotherapy

Published Date

2022/1

Aims The aim of this study was to investigate the efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention (PCI) stratified according to the baseline white blood cell (WBC) count. Methods and results This is a post hoc analysis of the GLOBAL LEADERS trial, a multi-centre, open-label, randomized all-comer trial in patients undergoing PCI, comparing the experimental strategy (23-month ticagrelor monotherapy following 1-month dual anti-platelet therapy [DAPT]) with the reference strategy (12-month aspirin monotherapy following 12-month DAPT). Patients were stratified into two WBC groups, either < or ≥median WBC count of 7.8 × 109 cells/L (lower or higher WBC group, respectively). The primary endpoint was a composite of all-cause mortality or new Q-wave myocardial infarction at 2 years. Of 14 576 patients included in the …

Effect of Wearing a Face Mask on Hand-to-Face Contact by Children in a Simulated School Environment: The Back-to-School COVID-19 Simulation Randomized Clinical Trial

Authors

Monica Caldeira-Kulbakas,Rulan S Parekh,Bryan R Maguire,Stacie Carroll,Samantha J Anthony,Ari Bitnun,Laura E Bourns,Douglas M Campbell,Eyal Cohen,Alison Dodds,Vinita Dubey,Jeremy N Friedman,Jodi L Greenwood,Jessica P Hopkins,Ryan Imgrund,Daphne J Korczak,Thomas Looi,Emily Louca,Dominik Mertz,John Nashid,Giovanna Panzera,Jane E Schneiderman,Kevin L Schwartz,Laurie Streitenberger,Sunayna Vuppal,Catharine M Walsh,Peter Jüni,Clyde T Matava,Upton Allen,Allison D Alvares,Catherine S Birken,Ahuva Brown,Vanessa L Carbone,Anne Christie,Maureen E Cividino,Justine H Cohen-Silver,Ronald D Cohn,Jennifer Crosbie,Bruno R da Costa,Blossom Dharmaraj,Sloane J Freeman,Karolina Gaebe,Omar Hajjaj,Lennox Huang,Sarah Khan,Eon Lee,Charlotte Logeman,Sanaz Manteghi,Clara Moore,Shaun K Morris,Julia Orkin,Sydney D Pelger,Lauren Pickel,Soha Salman,Ainslie Shouldice,Rachel Solomon,Nisha Thampi,Kevin Thorpe,Anna Wasiak,Jiayin Xie

Journal

JAMA pediatrics

Published Date

2022/12/1

ImportanceWearing a face mask in school can reduce SARS-CoV-2 transmission but it may also lead to increased hand-to-face contact, which in turn could increase infection risk through self-inoculation.ObjectiveTo evaluate the effect of wearing a face mask on hand-to-face contact by children while at school.Design, Setting, and ParticipantsThis prospective randomized clinical trial randomized students from junior kindergarten to grade 12 at 2 schools in Toronto, Ontario, Canada, during August 2020 in a 1:1 ratio to either a mask or control class during a 2-day school simulation. Classes were video recorded from 4 angles to accurately capture outcomes.InterventionsParticipants in the mask arm were instructed to bring their own mask and wear it at all times. Students assigned to control classes were not required to mask at any time (grade 4 and lower) or in the classroom where physical distancing could be …

Underweight in the first 2 years of life and growth in later childhood

Authors

Courtney A South,Charles DG Keown-Stoneman,Catherine S Birken,Vasanti S Malik,Stanley H Zlotkin,Jonathon L Maguire,Catherine Birken,Jonathon Maguire,Christopher Allen,Laura Anderson,Dana Arafeh,Mateenah Jaleel,Charles Keown-Stoneman,Natricha Levy McFarlane,Jessica Omand,Mary Aglipay,Imaan Bayoumi,Cornelia Borkhoff,Sarah Carsley,Katherine Cost,Curtis D'Hollander,Anne Fuller,Laura Kinlin,Patricia Li,Pat Parkin,Nav Persaud,Izabela Socynska,Shelley Vanderhout,Leigh Vanderloo,Peter Wong,Xuedi Li,Michelle Mitchell,Hakimat Shaibu,Yulika Yoshida-Montezuma,Marivic Bustos,Pamela Ruth Flores,Martin Ogwuru,Sharon Thadani,Julia Thompson,Laurie Thompson,Kardelen Kurt,Ataat Malick,Jennifer Batten,Jennifer Chan,John Clark,Maureen Colford,Amy Craig,Kim De Castris-Garcia,Sharon Dharman,Anthony Garcia,Sarah Kelleher,Sandra Marquez,Salimah Nasser,Tammara Pabon,Michelle Rhodes,Rafael Salsa,Jia Shin,Julie Skelding,Daniel Stern,Kerry Stewart,Erika Sendra Tavares,Shannon Weir,Maria Zaccaria,Magdalena Janus,Eric Duku,Caroline Reid-Westoby,Patricia Raso,Amanda Offord,Emy Abraham,Sara Ali,Kelly Anderson,Gordon Arbess,Jillian Baker,Tony Barozzino,Sylvie Bergeron,Gary Bloch,Joey Bonifacio,Ashna Bowry,Caroline Calpin,Douglas Campbell,Sohail Cheema,Elaine Cheng,Brian Chisamore,Evelyn Constantin,Karoon Danayan,Paul Das,Viveka De Guerra,Mary Beth Derocher,Anh Do,Kathleen Doukas,Anne Egger,Allison Farber,Amy Freedman,Sloane Freeman,Sharon Gazeley,Karen Grewal,Charlie Guiang,Dan Ha,Curtis Handford,Laura Hanson,Leah Harrington,Sheila Jacobson,Lukasz Jagiello,Gwen Jansz,Paul Kadar,Lukas Keiswetter,Tara Kiran,Holly Knowles,Bruce Kwok,Piya Lahiry,Sheila Lakhoo,Margarita Lam-Antoniades,Eddy Lau,Denis Leduc,Fok-Han Leung,Alan Li,Roy Male,Aleks Meret,Elise Mok,Rosemary Moodie,Katherine Nash,James Owen,Michael Peer,Marty Perlmutar,Navindra Persaud,Andrew Pinto,Michelle Porepa,Vikky Qi,Noor Ramji,Danyaal Raza,Katherine Rouleau,Caroline Ruderman,Janet Saunderson,Vanna Schiralli,Michael Sgro,Hafiz Shuja,Farah Siam,Susan Shepherd,Cinntha Srikanthan,Carolyn Taylor,Stephen Treherne,Suzanne Turner,Fatima Uddin,Meta van den Heuvel,Thea Weisdorf,John Yaremko,Ethel Ying,Elizabeth Young,Michael Zajdman,Peter Juni

Journal

JAMA Network Open

Published Date

2022/7/1

ImportanceFew studies have examined the association between underweight in the first 2 years and growth in later childhood in high-income countries.ObjectiveTo evaluate the associations of underweight in the first 2 years of life with body mass index (calculated as weight in kilograms divided by height in meters squared)zscore (zBMI), weight-for-agezscore (WAZ), and height-for-agezscore (HAZ) from ages 2 to 10 years.Design, Setting, and ParticipantsThis prospective cohort study was conducted between February 2008 to September 2020 in The Applied Research Group for Kids! practice-based research network in Toronto, Canada. Participants included healthy children aged 0 to 10 years. Data were analyzed from October 2020 to December 2021.ExposuresUnderweight (ie, zBMI less than −2, per the World Health Organization) in the first 2 years of life.Main Outcomes and MeasuresThe primary outcome was …

A randomized trial comparing axillary versus innominate artery cannulation for aortic arch surgery

Authors

Mark D Peterson,Vinay Garg,C David Mazer,Michael WA Chu,John Bozinovski,François Dagenais,Roderick GG MacArthur,Maral Ouzounian,Adrian Quan,Peter Jüni,Deepak L Bhatt,Thomas R Marotta,Jeffrey Dickson,Hwee Teoh,Fei Zuo,Eric E Smith,Subodh Verma,M Nazir Khan,Feryal Saad,Muhammad Mamdani,David A Latter,Thomas F Floyd,Paul WM Fedak,Aditya Bharatha,Judith Hall,Danusha Nadamalavan,Mohammed Al-Omran,Ismail El-Hamamsy,Kevin E Thorpe

Journal

The Journal of Thoracic and Cardiovascular Surgery

Published Date

2022/11/1

BackgroundCerebral protection remains the cornerstone of successful aortic surgery; however, there is no consensus as to the optimal strategy.ObjectiveTo compare the safety and efficacy of innominate to axillary artery cannulation for delivering antegrade cerebral protection during proximal aortic arch surgery.MethodsThis randomized controlled trial (The Aortic Surgery Cerebral Protection Evaluation CardioLink-3 Trial, ClinicalTrials.gov Identifier: NCT02554032), conducted across 6 Canadian centers between January 2015 and June 2018, allocated 111 individuals to innominate or axillary artery cannulation. The primary safety outcome was neuroprotection per the appearance of new severe ischemic lesions on the postoperative diffusion-weighted-magnetic resonance imaging. The primary efficacy outcome was the difference in total operative time. Secondary outcomes included 30-day all-cause mortality and …

2021 ESC/EACTS Guideline on the diagnosis and treatment of valvular heart disease: Developed by the European Society of Cardiology (ESC) and the European Association for Cardio …

Authors

A Vahanian,F Beyersdorf,F Praz,M Milojevic,S Baldus,J Bauersachs,D Capodanno,L Conradi,M De Bonis,R De Paulis,V Delgado,N Freemantle,M Gilard,KH Haugaa,A Jeppsson,P Jüni,L Pierard,BD Prendergast,J Rafael Sádaba,C Tribouilloy,W Wojakowski

Journal

Revista Espanola de Cardiologia

Published Date

2022

The True Infection Rate (TIR) in the whole population of each country and the Infection Fatality Rate (IFR) for coronavirus disease 2019 (COVID-19) are unknown although they are important parameters. We devised a simple method to infer TIR and IFR based on the open data. The prevalence rate of the polymerase chain reaction (PCR) tests among the population (Examination Rate; ER) and the positive rate of PCR tests (Infection Rate; IR) for 66 countries were picked up at a website 5 times from April 10th to June 13th, 2020, and the trajectory of each country was drawn over the IR vs. ER plot. IR and ER showed a strong negative correlation for some countries, and TIR was estimated by extrapolating the regression line when the correlation coefficient was between-0.99 and-1. True/Identified Case Ratio (TICR) and IFR were also calculated using the estimated TIR. The estimated TIR well coincided with local antibody surveys. Estimated IFR took on a wide range of values up to 10% generally high in the Western countries. The estimated IFR of Singapore was very low (0.018%), which may be related to the reported gene mutation causing the attenuation of the viral virulence.

Evidence-based recommendations on the use of nirmatrelvir/ritonavir (Paxlovid) for adults in Ontario

Authors

AS Komorowski,A Tseng,S Vandersluis,E Leung,W Ciccotelli,BJ Langford,N Andany,F Razak,W Wadhwa,P Jüni

Journal

Science briefs of the Ontario COVID-19 science advisory table

Published Date

2022/2/23

Declarations of Interest: The declarations of interest of the members of the Ontario COVID-19 Science Advisory Table, its Working Groups, or its partners can be found at https://covid19-sciencetable. ca/. The declarations of interest of external authors can be found under additional resources at https://doi. org/10.47326/ocsat. 2022.03. 57.1. 0About Us: The Ontario COVID-19 Science Advisory Table is a group of scientific experts and health system leaders who evaluate and report on emerging evidence relevant to the COVID-19 pandemic, to inform Ontario’s response. Our mandate is to provide weekly summaries of relevant scientific evidence for the COVID-19 Health Coordination Table of the Province of Ontario, integrating information from existing scientific tables, Ontario’s universities and agencies, and the best global evidence. The Science Table summarizes its findings for the Health Coordination Table and the public in Science Briefs.

Efficacy of topical progesterone versus topical clobetasol propionate in patients with vulvar Lichen sclerosus–A double-blind randomized phase II pilot study

Authors

Andreas R Günthert,Andreas Limacher,Helmut Beltraminelli,Elke Krause,Michael D Mueller,Sven Trelle,Pavlos Bobos,Peter Jüni

Journal

European Journal of Obstetrics & Gynecology and Reproductive Biology

Published Date

2022/5/1

BackgroundLichen sclerosus (LS) is a chronic inflammatory skin disease that mostly affects the anogenital region of women and lowers patients’ quality of life. Current standard treatment of LS is topical steroids.ObjectiveTo evaluate the efficacy of topical progesterone 8% ointment and compare to standard therapy with topical clobetasol propionate 0.05% in premenopausal women presenting with previously untreated early onset LS.Study designRandomized, double-blind, 2-arm, single center superiority trial in premenopausal women with histologically confirmed vulvar LS who were randomized in a 1:1 ratio to receive clobetasol propionate 0.05% ointment or progesterone 8% ointment. The primary outcome was the clinical severity LS score after 12 weeks, which consists of six clinical features assessed by the physician. Secondary outcomes were the symptom severity LS score, which consists of three symptoms …

PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY

Authors

Felice Gragnano,Dik Heg,Anna Franzone,Eugène P McFadden,Sergio Leonardi,Raffaele Piccolo,Pascal Vranckx,Mattia Branca,Patrick W Serruys,Edouard Benit,Christoph Liebetrau,Luc Janssens,Maurizio Ferrario,Aleksander Zurakowski,Roberto Diletti,Marcello Dominici,Kurt Huber,Ton Slagboom,Paweł Buszman,Leonardo Bolognese,Carlo Tumscitz,Krzysztof Bryniarski,Adel Aminian,Mathias Vrolix,Ivo Petrov,Scot Garg,Christoph Naber,Janusz Prokopczuk,Christian Hamm,Philippe Gabriel Steg,Peter Jüni,Stephan Windecker,Marco Valgimigli

Journal

European Heart Journal-Cardiovascular Pharmacotherapy

Published Date

2022/1

Aims The five-item PRECISE-DAPT, integrating age, haemoglobin, white-blood-cell count, creatinine clearance, and prior bleeding, predicts bleeding risk in patients on dual antiplatelet therapy (DAPT) after stent implantation. We sought to assess whether the bleeding risk prediction offered by the PRECISE-DAPT remains valid among patients receiving ticagrelor monotherapy from 1 month onwards after coronary stenting instead of standard DAPT and having or not having centrally adjudicated bleeding endpoints. Methods and results The PRECISE-DAPT was calculated in 14 928 and 7134 patients from GLOBAL LEADERS and GLASSY trials, respectively. The ability of the score to predict Bleeding Academic Research Consortium 3 or 5 bleeding was assessed and compared among patients on ticagrelor monotherapy (experimental strategy) or standard DAPT (reference …

The Empower Study-Design of a Randomized Clinical Trial to Assess the Efficacy and Safety of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate for Heavy Menstrual …

Authors

Michelle Sholzberg,Grace H Tang,Paula D James,Filomena Meffe,Emily Rimmer,Shannon Jackson,Haowei Linda Sun,Sue Robinson,Georgina Floros,Shamshah Aratia,Peter Jüni,Bruno R da Costa

Journal

Blood

Published Date

2022/11/15

Background: Although von Willebrand disease (VWD) is inherited by men and women equally, women are more likely to experience bleeding symptoms due to the challenges of menstruation and childbirth. Heavy menstrual bleeding (HMB) is the most common symptom observed in women and girls with VWD, and increases risk of iron deficiency anemia, blood transfusion, hospitalization and decreased health-related quality of life. While replacement therapy with von Willebrand factor (VWF) is recommended for prophylaxis in patients with VWD with severe and frequent bleeding, recommendations on its use for prophylaxis of HMB are limited due the lack of clinical trial data.Aims: The EMPOWER pilot trial will determine the feasibility of the trial design, as well as explore assay sensitivity to inform the determination of the primary outcome for the definitive randomized trial which will evaluate the effect of prophylaxis …

Design details for overdose education and take‐home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community

Authors

Kate Sellen,Nick Goso,Laura Halleran,Alison Mulvale‐Fletcher,Felipe Sarmiento,Filipe Ligabue,Curtis Handford,Michelle Klaiman,Geoffrey Milos,Amy Wright,Mercy Charles,Ruby Sniderman,Richard Hunt,Janet A Parsons,Pamela Leece,Shaun Hopkins,Rita Shahin,Peter Jüni,Laurie Morrison,Douglas M Campbell,Carol Strike,Aaron Orkin,SOONER Investigators

Journal

Health Expectations

Published Date

2022/10

Introduction Overdose education and naloxone distribution (OEND) programmes equip and train people who are likely to witness an opioid overdose to respond with effective first aid interventions. Despite OEND expansion across North America, overdose rates are increasing, raising questions about how to improve OEND programmes. We conducted an iterative series of codesign stakeholder workshops to develop a prototype for take‐home naloxone (THN)‐kit (i.e., two doses of intranasal naloxone and training on how to administer it). Methods We recruited people who use opioids, frontline healthcare providers and public health representatives to participate in codesign workshops covering questions related to THN‐kit prototypes, training on how to use it, and implementation, including refinement of design artefacts using personas and journey maps. Completed over 9 months, the workshops were audio …

Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial

Authors

Masafumi Ono,Yoshinobu Onuma,Hideyuki Kawashima,Hironori Hara,Chao Gao,Rutao Wang,Neil O'Leary,Edouard Benit,Luc Janssens,Maurizio Ferrario,Aleksander Żurakowski,Marcello Dominici,Kurt Huber,Paweł Buszman,Scot Garg,Joanna J Wykrzykowska,Jan J Piek,Peter Jüni,Christian Hamm,Stephan Windecker,Pascal Vranckx,Efthymios N Deliargyris,Deepak L Bhatt,Robert F Storey,Marco Valgimigli,Patrick W Serruys,GLOBAL LEADERS trial investigators

Journal

Catheterization and Cardiovascular Interventions

Published Date

2022/7

Background Several studies have suggested that proton pump inhibitors (PPIs) may reduce the antiplatelet effects of clopidogrel and/or aspirin, possibly leading to cardiovascular events. Aims We aimed to investigate the association between PPI and clinical outcomes in patients treated with ticagrelor monotherapy or conventional antiplatelet therapy after percutaneous coronary intervention (PCI). Methods This is a subanalysis of the randomized GLOBAL LEADERS trial, comparing the experimental antiplatelet arm (23‐month ticagrelor monotherapy following 1‐month dual antiplatelet therapy [DAPT]) with the reference arm (12‐month aspirin monotherapy following 12‐month DAPT) after PCI. Patient‐oriented composite endpoints (POCEs: all‐cause mortality, myocardial infarction, stroke, or repeat revascularization) and its components were assessed stratified by PPI use as a time‐dependent covariate in …

2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of …

Authors

Alec Vahanian,Friedhelm Beyersdorf,Fabien Praz,Milan Milojevic,Stephan Baldus,Johann Bauersachs,Davide Capodanno,Lenard Conradi,Michele De Bonis,Ruggero De Paulis,Victoria Delgado,Nick Freemantle,Martine Gilard,Kristina H Haugaa,Anders Jeppsson,Peter Jüni,Luc Pierard,Bernard D Prendergast,J Rafael Sadaba,Christophe Tribouilloy,Wojtek Wojakowski

Published Date

2022/2/14

Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC/EACTS Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the healthcare professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.

Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort

Authors

Sabri Soussi,Divya Sharma,Peter Jüni,Gerald Lebovic,Laurent Brochard,John C Marshall,Patrick R Lawler,Margaret Herridge,Niall Ferguson,Lorenzo Del Sorbo,Elodie Feliot,Alexandre Mebazaa,Erica Acton,Jason N Kennedy,Wei Xu,Etienne Gayat,Claudia C Dos Santos,FROG-ICU Soussi Sabri Mebazaa Alexandre Gayat Etienne,CCCTBG trans-trial group study for InFACT-the International Forum for Acute Care Trialists Soussi Sabri Brochard Laurent Marshall John C. Herridge Margaret Dos Santos Claudia C.

Journal

Critical Care

Published Date

2022/4/21

BackgroundLate mortality risk in sepsis-survivors persists for years with high readmission rates and low quality of life. The present study seeks to link the clinical sepsis-survivors heterogeneity with distinct biological profiles at ICU discharge and late adverse events using an unsupervised analysis. MethodsIn the original FROG-ICU prospective, observational, multicenter study, intensive care unit (ICU) patients with sepsis on admission (Sepsis-3) were identified (N = 655). Among them, 467 were discharged alive from the ICU and included in the current study. Latent class analysis was applied to identify distinct sepsis-survivors clinical classes using readily available data at ICU discharge. The primary endpoint was one-year mortality after ICU discharge.ResultsAt ICU discharge, two distinct subtypes were identified (A and B) using 15 readily available clinical and biological variables. Patients assigned to subtype B …

Association of atrial septal aneurysm and shunt size with stroke recurrence and benefit from patent foramen ovale closure

Authors

Jean-Louis Mas,Jeffrey L Saver,Scott E Kasner,Jason Nelson,John D Carroll,Gilles Chatellier,Geneviève Derumeaux,Anthony J Furlan,Howard C Herrmann,Peter Jüni,Jong S Kim,Benjamin Koethe,Pil Hyung Lee,Benedicte Lefebvre,Heinrich P Mattle,Bernhard Meier,Mark Reisman,Richard W Smalling,Lars Sondergaard,Jae-Kwan Song,David E Thaler,David M Kent

Journal

JAMA neurology

Published Date

2022/11/1

ImportanceThe Patent Foramen Ovale (PFO)–Associated Stroke Causal Likelihood classification system combines information regarding noncardiac patient features (vascular risk factors, infarct topography) and PFO features (shunt size and presence of atrial septal aneurysm [ASA]) to classify patients into 3 validated categories of responsiveness to treatment with PFO closure. However, the distinctive associations of shunt size and ASA, alone and in combination, have not been completely delineated.ObjectiveTo evaluate the association of PFO closure with stroke recurrence according to shunt size and/or the presence of an ASA.Design, Setting, and ParticipantsPooled individual patient data from 6 randomized clinical trials conducted from February 2000 to October 2017 that compared PFO closure with medical therapy. Patients in North America, Europe, Australia, Brazil, and South Korea with PFO-associated …

Is internal rotation measurement of the hip useful for ruling in cam or pincer morphology in asymptomatic males? A diagnostic accuracy study

Authors

Roger Hilfiker,Marc Hunkeler,Andreas Limacher,Michael Leunig,Harald Bonel,Matthias Egger,Peter Jüni,Stephan Reichenbach

Journal

Clinical Orthopaedics and Related Research®

Published Date

2022/10/1

BackgroundCam and pincer morphologies are associated with limited internal rotation. However, the routine clinical examination for hip rotation has limited reliability. A more standardized method of measuring hip rotation might increase test-retest and interobserver reliability and might be useful as a screening test to detect different hip morphologies without the need for imaging. We developed an examination chair to standardize the measurement of internal hip rotation, which improved interobserver reliability. However, the diagnostic test accuracy for this test is unknown.

Guía ESC/EACTS 2021 sobre el diagnóstico y tratamiento de las valvulopatías: Desarrollada por el Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) y la European …

Authors

Alec Vahanian,Friedhelm Beyersdorf,Fabien Praz,Milan Milojevic,Stephan Baldus,Johann Bauersachs,Davide Capodanno,Lenard Conradi,Michele De Bonis,Ruggero De Paulis,Victoria Delgado,Nick Freemantle,Martine Gilard,Kristina H Haugaa,Anders Jeppsson,Peter Jüni,Luc Pierard,Bernard D Prendergast,J Rafael Sádaba,Christophe Tribouilloy,Wojtek Wojakowski

Journal

Revista Española de Cardiología

Published Date

2022/6/1

The True Infection Rate (TIR) in the whole population of each country and the Infection Fatality Rate (IFR) for coronavirus disease 2019 (COVID-19) are unknown although they are important parameters. We devised a simple method to infer TIR and IFR based on the open data. The prevalence rate of the polymerase chain reaction (PCR) tests among the population (Examination Rate; ER) and the positive rate of PCR tests (Infection Rate; IR) for 66 countries were picked up at a website 5 times from April 10th to June 13th, 2020, and the trajectory of each country was drawn over the IR vs. ER plot. IR and ER showed a strong negative correlation for some countries, and TIR was estimated by extrapolating the regression line when the correlation coefficient was between -0.99 and -1. True/Identified Case Ratio (TICR) and IFR were also calculated using the estimated TIR. The estimated TIR well coincided with local …

Readers’ Comments 139

Authors

F Costa,A Jeppsson,P Jüni,A Kastrati,P Kolh,L Mauri,G Montalescot,FJ Neumann

Journal

Am J Cardiol

Published Date

2022

A recent meta-analysis assessed short-term DAPT (1 to 3 months) versus standard DAPT (12 to 24 months) and reported lower bleeding risks with similar ischemic events using the abbreviated DAPT duration. 3 More recent evidence accumulated since then for even shorter duration (1-month DAPT) has shown promising results.[...] we conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the safety and efficacy of 1-month DAPT in this population. Newer-generation stents probably play a role in mitigating the ischemic events after PCI (stent thrombosis, in-stent restenosis, and so on). 3 Thereby, shorter DAPT duration led to fewer bleeding events with retention of ischemic benefits.[...] in patients who underwent PCI, 1-month DAPT followed by SAPT might be a safe and effective alternative compared with standard DAPT (≥ 3 months).

Clinical trial design principles and outcomes definitions for device-based therapies for hypertension: a consensus document from the hypertension academic research consortium

Authors

David E Kandzari,Felix Mahfoud,Michael A Weber,Raymond Townsend,Gianfranco Parati,Naomi DL Fisher,Melvin D Lobo,Michael Bloch,Michael Böhm,Andrew SP Sharp,Roland E Schmieder,Michel Azizi,Markus P Schlaich,Vasilios Papademetriou,Ajay J Kirtane,Joost Daemen,Atul Pathak,Christian Ukena,Philipp Lurz,Guido Grassi,Martin Myers,Aloke V Finn,Marie-Claude Morice,Roxana Mehran,Peter Jüni,Gregg W Stone,Mitchell W Krucoff,Paul K Whelton,Konstantinos Tsioufis,Donald E Cutlip,Ernest Spitzer

Published Date

2022/3/15

The clinical implications of hypertension in addition to a high prevalence of both uncontrolled blood pressure and medication nonadherence promote interest in developing device-based approaches to hypertension treatment. The expansion of device-based therapies and ongoing clinical trials underscores the need for consistency in trial design, conduct, and definitions of clinical study elements to permit trial comparability and data poolability. Standardizing methods of blood pressure assessment, effectiveness measures beyond blood pressure alone, and safety outcomes are paramount. The Hypertension Academic Research Consortium (HARC) document represents an integration of evolving evidence and consensus opinion among leading experts in cardiovascular medicine and hypertension research with regulatory perspectives on clinical trial design and methodology. The HARC document integrates the …

Comparative frequency and prognostic impact of myocardial injury in hospitalized patients with COVID-19 and influenza

Authors

Luigi Biasco,Catherine Klersy,Giulia S Beretta,Marco Valgimigli,Amabile Valotta,Luca Gabutti,Roberto Della Bruna,Alberto Pagnamenta,Gregorio Tersalvi,Lorenzo Ruinelli,Andrea Artero,Gaetano Senatore,Peter Jüni,Giovanni B Pedrazzini

Journal

European Heart Journal Open

Published Date

2021/11/1

Aims Myocardial injury (MINJ) in Coronavirus disease 2019 (COVID-19) identifies individuals at high mortality risk but its clinical relevance is less well established for Influenza and no comparative analyses evaluating frequency and clinical implications of MINJ among hospitalized patients with Influenza or COVID-19 are available. Methods and results Hospitalized adults with laboratory confirmed Influenza A or B or COVID-19 underwent highly sensitive cardiac T Troponin (hs-cTnT) measurement at admission in four regional hospitals in Canton Ticino, Switzerland. MINJ was defined as hs-cTnT >14 ng/L. Clinical, laboratory and outcome data were retrospectively collected. The primary outcome was mortality up to 28 days. Cox regression models were used to assess correlations between admission diagnosis, MINJ, and mortality. Clinical correlates of MINJ in both viral …

Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial

Authors

Darrell HS Tan,Adrienne K Chan,Peter Jüni,George Tomlinson,Nick Daneman,Sharon Walmsley,Matthew Muller,Rob Fowler,Srinivas Murthy,Natasha Press,Curtis Cooper,Todd Lee,Tony Mazzulli,Allison McGeer

Journal

Trials

Published Date

2021/12

Background Post-exposure prophylaxis (PEP) is a well-established strategy for the prevention of infectious diseases, in which recently exposed people take a short course of medication to prevent infection. The primary objective of the COVID-19 Ring-based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR) is to evaluate the efficacy of a 14-day course of oral lopinavir/ritonavir as PEP against COVID-19 among individuals with a high-risk exposure to a confirmed case. Methods This is an open-label, multicenter, 1:1 cluster-randomized trial of LPV/r 800/200 mg twice daily for 14 days (intervention arm) versus no intervention (control arm), using an adaptive approach to sample size calculation. Participants will be individuals aged > 6 months with a high-risk exposure to a confirmed COVID-19 case within the past 7 days. A combination of remote …

Rapid antigen tests for voluntary screen testing

Authors

P Jüni,S Baert,P Bobos

Journal

Science Briefs of the Ontario COVID-19 Science Advisory Table

Published Date

2021/12/9

Declarations of Interest: The declarations of interest of the members of the Ontario COVID-19 Science Advisory Table, its Working Groups, or its partners can be found at https://covid19-sciencetable. ca/. The declarations of interest of external authors can be found under additional resources at https://doi. org/10.47326/ocsat. 2021.02. 52.1. 0About Us: The Ontario COVID-19 Science Advisory Table is a group of scientific experts and health system leaders who evaluate and report on emerging evidence relevant to the COVID-19 pandemic, to inform Ontario’s response. Our mandate is to provide weekly summaries of relevant scientific evidence for the COVID-19 Health Coordination Table of the Province of Ontario, integrating information from existing scientific tables, Ontario’s universities and agencies, and the best global evidence. The Science Table summarizes its findings for the Health Coordination Table and the public in Science Briefs.

The role of wastewater testing for SARS-CoV-2 surveillance

Authors

Douglas G Manuel,Robert Delatolla,David Fisman,Meghan Fuzzen,Tyson E Graber,Gabrielle M Katz,JinHee Kim,Chrystal Landgraff,Alex MacKenzie,Antonina Maltsev,Anna Majury,R Michael McKay,John Minnery,Mark Servos,J Scott Weese,Allison McGeer,Karen B Born,Kali Barrett,Brian Schwartz,Peter Jüni

Published Date

2021/8/26

Wastewater testing for SARS-CoV-2 is relatively new; however, it builds on existing public health surveillance infrastructure. There is a limited but growing evidence base for its use, despite notable interpretation challenges. Wastewater testing results have helped to inform public health policy and interventions during the COVID-19 pandemic in Ontario and other jurisdictions. Wastewater testing for SARS-CoV-2 is useful for early detection of outbreaks and surges as well as population-wide surveillance of COVID-19 that is complementary to clinical testing. Further, it offers an efficient means of SARS-CoV-2 surveillance for specific settings such as correctional facilities, shelters, and university residences. Wastewater testing can also be used for the detection and monitoring of variants of concern (VOCs).

Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression

Authors

Ayodele Odutayo,Bruno R da Costa,Tiago V Pereira,Vinay Garg,Samir Iskander,Fatimah Roble,Rahim Lalji,Cesar A Hincapié,Aquila Akingbade,Myanca Rodrigues,Arnav Agarwal,Bishoy Lawendy,Pakeezah Saadat,Jacob A Udell,Francesco Cosentino,Peter J Grant,Subodh Verma,Peter Jüni

Published Date

2021/9/21

Background This study aimed to assess the effectiveness of sodium‐glucose cotransporter 2 inhibitors in reducing the incidence of mortality and cardiovascular outcomes in adults with type 2 diabetes. Methods and Results We conducted a Bayesian meta‐analysis of randomized controlled trials comparing sodium‐glucose cotransporter 2 inhibitors with placebo. We used meta‐regression to examine the association between treatment effects and control group event rates as measures of cardiovascular baseline risk. Fifty‐three randomized controlled trials were included in our synthesis. Empagliflozin, canagliflozin, and dapagliflozin reduced the incidence of all‐cause mortality (empagliflozin: rate ratio [RR], 0.79; 95% credibility interval [CrI], 0.63–0.97; canagliflozin: RR, 0.86; 95% CrI, 0.69–1.05; dapagliflozin: RR, 0.86; 95% CrI, 0.72–1.01) and cardiovascular mortality (empagliflozin: RR, 0.78; 95% CrI, 0.61–1.00 …

Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial

Authors

Pieter C Smits,Enrico Frigoli,Jan Tijssen,Peter Jüni,Pascal Vranckx,Yukio Ozaki,Marie-Claude Morice,Bernard Chevalier,Yoshinobu Onuma,Stephan Windecker,Pim AL Tonino,Marco Roffi,Maciej Lesiak,Felix Mahfoud,Jozef Bartunek,David Hildick-Smith,Antonio Colombo,Goran Stankovic,Andrés Iñiguez,Carl Schultz,Ran Kornowski,Paul JL Ong,Mirvat Alasnag,Alfredo E Rodriguez,Aris Moschovitis,Peep Laanmets,Dik Heg,Marco Valgimigli,MASTER DAPT Investigators

Journal

Circulation

Published Date

2021/10/12

Background The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or without oral anticoagulation (OAC) after coronary stenting remains unclear. Methods In the investigator-initiated, randomize, open-label MASTER DAPT trial (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen), 4579 patients at high bleeding risk were randomized after 1-month dual APT to abbreviated or nonabbreviated APT strategies. Randomization was stratified by concomitant OAC indication. In this subgroup analysis, we report outcomes of populations with or without an OAC indication. In the population with an OAC indication, patients changed immediately to single APT for 5 months (abbreviated regimen) or continued ≥2 months of dual APT and single APT thereafter (nonabbreviated regimen). Patients …

A disproportionate epidemic: COVID-19 cases and deaths among essential workers in Toronto, Canada

Authors

Amrita Rao,Huiting Ma,Gary Moloney,Jeffrey C Kwong,Peter Jüni,Beate Sander,Rafal Kustra,Stefan D Baral,Sharmistha Mishra

Journal

Annals of epidemiology

Published Date

2021/11/1

Shelter-in-place mandates and closure of nonessential businesses have been central to COVID19 response strategies including in Toronto, Canada. Approximately half of the working population in Canada are employed in occupations that do not allow for remote work suggesting potentially limited impact of some of the strategies proposed to mitigate COVID-19 acquisition and onward transmission risks and associated morbidity and mortality. We compared per-capita rates of COVID-19 cases and deaths from January 23, 2020 to January 24, 2021, across neighborhoods in Toronto by proportion of the population working in essential services. We used person-level data on laboratory-confirmed COVID-19 community cases and deaths, and census data for neighborhood-level attributes. Cumulative per-capita rates of COVID-19 cases and deaths were 3.3-fold and 2.5-fold higher, respectively, in neighborhoods with …

Risk-stratification of febrile African children at risk of sepsis using sTREM-1 as basis for a rapid triage test

Authors

Aleksandra Leligdowicz,Andrea L Conroy,Michael Hawkes,Melissa Richard-Greenblatt,Kathleen Zhong,Robert O Opoka,Sophie Namasopo,David Bell,W Conrad Liles,Bruno R da Costa,Peter Jüni,Kevin C Kain

Journal

Nature Communications

Published Date

2021/11/25

Identifying febrile children at risk of sepsis in low-resource settings can improve survival, but recognition triage tools are lacking. Here we test the hypothesis that measuring circulating markers of immune and endothelial activation may identify children with sepsis at risk of all-cause mortality. In a prospective cohort study of 2,502 children in Uganda, we show that Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) measured at first clinical presentation, had high predictive accuracy for subsequent in-hospital mortality. sTREM-1 had the best performance, versus 10 other markers, with an AUROC for discriminating children at risk of death of 0.893 in derivation (95% CI 0.843–0.944) and 0.901 in validation (95% CI 0.856–0.947) cohort. sTREM-1 cutoffs corresponding to a negative likelihood ratio (LR) of 0.10 and a positive LR of 10 classified children into low (1,306 children, 53.1%), intermediate (942 …

Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization

Authors

Raffaele Piccolo,Kaare H Bonaa,Orestis Efthimiou,Olivier Varenne,Philip Urban,Christoph Kaiser,Lorenz Raeber,Adam de Belder,Wouter Remkes,Arnoud WJ Van’T Hof,Goran Stankovic,Pedro A Lemos,Tom Wilsgaard,Joerg Reifart,Alfredo E Rodriguez,Expedito E Ribeiro,Patrick WJC Serruys,Alex Abizaid,Manel Sabate,Robert A Byrne,Jose M de la Torre Hernandez,William Wijns,Giovanni Esposito,Peter Jueni,Stephan Windecker,Marco Valgimigli,Coronary Stent Trialists’(CST) Collaboration

Journal

Journal of the American Heart Association

Published Date

2021/10/19

Background New‐generation drug‐eluting stents (DES) reduce target‐vessel revascularization compared with bare‐metal stents (BMS), and recent data suggest that DES have the potential to decrease the risk of myocardial infarction and cardiovascular mortality. We evaluated the treatment effect of DES versus BMS according to the target artery (left anterior descending [LAD] and/or left main [LM] versus other territories [no‐LAD/LM]). Methods and Results The Coronary Stent Trialist (CST) Collaboration gathered individual patient data of randomized trials of DES versus BMS for the treatment of coronary artery disease. The primary outcome was the composite of cardiac death or myocardial infarction. Hazard ratios (HRs) with 95% CIs were derived from a 1‐stage individual patient data meta‐analysis. We included 26 024 patients across 19 trials: 13 650 (52.4%) in the LAD/LM and 12 373 (47.6%) in the no‐LAD …

Randomized trials of therapeutic heparin for COVID‐19: a meta‐analysis

Authors

Michelle Sholzberg,Bruno R da Costa,Grace H Tang,Hassan Rahhal,Musaad AlHamzah,Lisa Baumann Kreuziger,Fionnuala Ní Áinle,Mozah Obaid Almarshoodi,Paula D James,David Lillicrap,Marc Carrier,Andrew Beckett,Michael Fralick,Saskia Middeldorp,Agnes YY Lee,Kevin E Thorpe,Elnara Márcia Negri,Mary Cushman,Peter Jüni,RAPID Trial Investigators

Journal

Research and practice in thrombosis and haemostasis

Published Date

2021/12

Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute to hypoxemic respiratory failure, the most common cause of death, in patients with COVID‐19. Randomized controlled trials (RCTs) suggest differences in the effect of therapeutic heparin between moderately and severely ill patients with COVID‐19. We did a systematic review and meta‐analysis of RCTs to determine the effects of therapeutic heparin in hospitalized patients with COVID‐19. Methods We searched PubMed, Embase, Web of Science, medRxiv, and medical conference proceedings for RCTs comparing therapeutic heparin with usual care, excluding trials that used oral anticoagulation or intermediate doses of heparin in the experimental arm. Mantel‐Haenszel fixed‐effect meta‐analysis was used to combine odds ratios (ORs). Results and Conclusions There were 3 RCTs that compared therapeutic heparin to …

The impact of the COVID-19 pandemic on opioid-related harm in Ontario

Authors

Erik L Friesen,Paul A Kurdyak,Tara Gomes,Gillian Kolla,Pamela Leece,Lynn Zhu,Elaine Toombs,Braden O’Neill,Nathan M Stall,Peter Jüni,CJ Mushquash,L Mah

Journal

Science Briefs of the Ontario COVID-19 Science Advisory Table

Published Date

2021/9/8

BackgroundRates of opioid-related harm, particularly fatal overdose, have increased significantly in Ontario during the COVID-19 pandemic. Reducing the burden of opioid-related harm among people who use drugs (PWUD) will require systematic interventions and ongoing evaluation of the effectiveness of these interventions.

Revisiting the evidence for physical distancing, face masks, and eye protection

Authors

Mohamed Abbas,Michihiko Goto,Ermira Tartari,Eli Perencevich,Didier Pittet

Journal

The Lancet

Published Date

2021/8/21

The systematic review included literature up to May 3, 2020. Seven articles, including four preprints, described the comparison of the risk of SARS-CoV-2 transmission between far and short physical distancing. Further physical distancing was associated with a lower risk of SARS-CoV-2 transmission (relative risk [RR] 0· 15 compared with shorter physical distancing, 95% CI 0· 03–0· 73, I²= 59%; appendix).We followed up on the status of the four preprints and found that one of them2 was published online on May 1, 2020, 3 before the search cutoff date. The published version used a larger dataset (n= 227 vs n= 83 in the preprint), and the risk of SARS-CoV-2 transmission was almost equal between the physical distancing groups (RR 0· 99 vs RR 0· 55 in the preprint). We updated the meta-analysis, replacing the results from the preprint by the corresponding published study. 3 The association between physical …

Efficacy and safety of early aspirin withdrawal and continuation of ticagrelor monotherapy post PCI for STEMI. A post hoc analysis of the randomized global leaders trial

Authors

A Gamal Setih,H Hara,M Tomaniak,M Lunardi,C Gao,M Ono,H Kawashima,P Juni,Pascal VRANCKX,S Windecker,C Hamm,P Gabriel Steg,Y Onuma,P Serruys

Published Date

2021

Issue Date: 2021 Publisher: OXFORD UNIV PRESS Source: EUROPEAN HEART JOURNAL, 42, p. 2998-2998 Document URI: http://hdl. handle. net/1942/36273 ISSN: 0195-668X e-ISSN: 1522-9645 ISI#: WOS: 000720456903299 Category: M Type: Journal Contribution

Dual antiplatelet therapy after PCI in patients at high bleeding risk

Authors

Marco Valgimigli,Enrico Frigoli,Dik Heg,Jan Tijssen,Peter Jüni,Pascal Vranckx,Yukio Ozaki,Marie-Claude Morice,Bernard Chevalier,Yoshinobu Onuma,Stephan Windecker,Pim AL Tonino,Marco Roffi,Maciej Lesiak,Felix Mahfoud,Jozef Bartunek,David Hildick-Smith,Antonio Colombo,Goran Stanković,Andres Iniguez,Carl Schultz,Ran Kornowski,Paul JL Ong,Mirvat Alasnag,Alfredo E Rodriguez,Aris Moschovitis,Peep Laanmets,Michael Donahue,Sergio Leonardi,Pieter C Smits

Journal

New England Journal of Medicine

Published Date

2021/10/28

Background The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods One month after they had undergone implantation of a biodegradable-polymer sirolimus-eluting coronary stent, we randomly assigned patients at high bleeding risk to discontinue dual antiplatelet therapy immediately (abbreviated therapy) or to continue it for at least 2 additional months (standard therapy). The three ranked primary outcomes were net adverse clinical events (a composite of death from any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (a composite of death from any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding; cumulative incidences were assessed at 335 days. The first two outcomes were assessed for noninferiority in the …

Issue Note Key considerations for introducing and lifting public health measures in kindergarten, elementary, secondary, and post-secondary schools

Authors

Peter Jüni

Published Date

2021/10/18

The 2021-2022 academic year has already begun and there has been significant media coverage and discussion regarding how schools should operate. Vaccination rates and the emergence of novel and more contagious variants of concern, particularly the Delta variant, have shaped the evolution of the COVID-19 pandemic in Canada.This Issue Note answers the following question: For the 2021-2022 academic year, what are the key considerations to use in determining which public health measures are to be kept (eg masking) or introduced,(eg regular self-testing) in kindergarten, elementary, secondary, and postsecondary schools?

Pooled Analysis of Six Randomized Trials Comparing Device Closure of Patent Foramen Ovale After Stroke to Medical Treatment: Overall Effects and Patient Selection Using a …

Authors

David M Kent,Jeffrey L Saver,Scott E Kasner,Jason Nelson,John D Carroll,Gilles Chatellier,Geneviéve Derumeaux,Anthony J Furlan,Howard C Herrmann,Peter Juni,Jong S Kim,Benjamin Koethe,Pil Hyung Lee,Bénédicte Lefebvre,Heinrich P Mattle,Bernhard Meier,Mark Reisman,Richard W Smalling,Lars Soendergaard,Jae-kwan Song,Jean-Louis Mas,David E Thaler

Journal

Circulation

Published Date

2021/11/16

Introduction: Patent foramen ovale (PFO)-associated strokes account for ~10% of ischemic strokes in adults aged 18-60. Despite overall beneficial effects of device closure on stroke recurrence risk, the best treatment option for any individual patient is often unclear. Methods: We pooled individual participant-level data from all 6 RCTs comparing PFO closure with percutaneous devices plus medical therapy vs medical therapy alone. The primary outcome was recurrent ischemic stroke. We used Cox proportional hazards models to estimate adjusted HRs, with study-specific baseline hazards and a fixed treatment effect. Pre-specified primary subgroup analyses used the Risk of Paradoxical Embolism (RoPE) Score (a 10 point score with higher scores reflecting younger age and absence of vascular risk factors) and the PFO-Associated Stroke Causal Likelihood (PASCAL) algorithm, a classification system that combines …

Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial

Authors

Antonio Landi,Mattia Branca,Giuseppe Andò,Filippo Russo,Enrico Frigoli,Giuseppe Gargiulo,Carlo Briguori,Pascal Vranckx,Sergio Leonardi,Felice Gragnano,Paolo Calabrò,Gianluca Campo,Giuseppe Ambrosio,Andrea Santucci,Ferdinando Varbella,Tiziana Zaro,Dik Heg,Stephan Windecker,Peter Jüni,Giovanni Pedrazzini,Marco Valgimigli,MATRIX Investigators

Journal

European Heart Journal Acute Cardiovascular Care

Published Date

2021/12/1

Aims Acute kidney injury (AKI) is a critical complication among patients with acute coronary syndrome (ACS) undergoing invasive management. The value of adjunctive antithrombotic strategies, such as bivalirudin or unfractionated heparin (UFH) on the risk of AKI is unclear. Methods and results Among 7213 patients enrolled in the MATRIX-Antithrombin and Treatment Duration study, 128 subjects were excluded due to incomplete information on serum creatinine (sCr) or end-stage renal disease on dialysis treatment. The primary endpoint was AKI defined as an absolute (>0.5 mg/dL) or a relative (>25%) increase in sCr. AKI occurred in 601 patients (16.9%) treated with bivalirudin and 616 patients (17.4%) treated with UFH [odds ratio (OR): 0.97; 95% confidence interval (CI): 0.85–1.09; P = 0.58]. A >25% sCr increase was observed in 597 patients (16.8%) with bivalirudin and …

COVID‐19 and Ontario's long‐term care homes

Authors

Nathan M Stall,Kevin A Brown,Antonina Maltsev,Aaron Jones,Andrew P Costa,Vanessa Allen,Adalsteinn D Brown,Gerald A Evans,David N Fisman,Jennie Johnstone,Peter Jüni,Kamil Malikov,Allison McGeer,Paula A Rochon,Beate Sander,Brian Schwartz,Samir K Sinha,Kevin Smith,Ashleigh R Tuite,Michael P Hillmer

Journal

Journal of Elder Policy

Published Date

2021/9

Ontario long‐term care (LTC) home residents have experienced disproportionately high morbidity and mortality, both from COVID‐19 and from the conditions associated with the COVID‐19 pandemic. As of July 10, 2021, a total of 3,975 LTC home residents have died of COVID‐19, totaling 43.0% of all 9,245 COVID‐19 deaths in Ontario. The most important risk factors for whether a LTC home will experience an outbreak is the daily incidence of SARS‐CoV‐2 infections in the communities surrounding the home and the occurrence of staff infections. The most important risk factors for the magnitude of an outbreak and the number of resulting resident deaths are older design, chain ownership, and crowding. Many Ontario LTC home residents have experienced severe and potentially irreversible physical, cognitive, psychological, and functional declines as a result of precautionary public health interventions imposed …

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an …

Authors

Filippo Crea

Published Date

2021/8/14

We appreciate the interest on the 2020 European Society of Cardiology (ESC) guidelines for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation (NSTE-ACS). 1 The updated new guideline has considered the landmark trials published within the last 5 years to formulate updated, practical, and new recommendations. As such, the chairmen and the Task Force of the ESC guidelines support any scientific discussion on the guidelines, an essential component of their dissemination and implementation in clinical practice. The guidelines were presented at ESC Congress 2020, but the virtual nature of the meeting has limited the options of discussion. Among them is a debate on the class IIa level of evidence B recommendation on preference of prasugrel over ticagrelor for patients undergoing percutaneous coronary intervention (PCI) and to not recommend …

Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis

Authors

A Oliva,M Avvedimento,A Franzone,S Windecker,M Valgimigli,G Esposito,P Juni,R Piccolo

Published Date

2021/10/1

Background Bleeding is the principal safety concern of antithrombotic therapy and occurs frequently among patients with coronary artery disease (CAD). Aims We aim to evaluate the prognostic impact of bleeding on mortality compared with that of myocardial infarction (MI) in patients with CAD. Methods We searched Medline and Embase for studies that included patients with CAD and that reported both, the association between the occurrence of bleeding and mortality, and between the occurrence of MI and mortality within the same population. Adjusted hazard ratios (HRs) for mortality associated with bleeding and MI were extracted and ratio of hazard ratios (rHRs) were pooled by using inverse variance weighted random effects meta-analyses. Early events included periprocedural or within 30-day events after revascularization or acute coronary syndrome …

Age and sex specific prevalence of clinical and screen-detected atrial fibrillation in hospitalized patients

Authors

Laurent Roten,Eleni Goulouti,Anna Lam,Elena Elchinova,Nikolas Nozica,Alessandro Spirito,Severin Wittmer,Mattia Branca,Helge Servatius,Fabian Noti,Jens Seiler,Samuel H Baldinger,Andreas Haeberlin,Stefano De Marchi,Babken Asatryan,Nicolas Rodondi,Jacques Donzé,Drahomir Aujesky,Hildegard Tanner,Tobias Reichlin,Peter Jüni

Journal

Journal of clinical medicine

Published Date

2021/10/22

Background The prevalence of atrial fibrillation (AF) is high in older patients. The present study aimed to estimate the age and sex specific prevalence of clinical and screen-detected atrial fibrillation (AF) in hospitalized patients. Methods The STAR-FIB cohort study was a prospective cohort study recruiting participants from a large source population of hospitalized patients aged 65–84 years. The estimated size of the source population was 26,035 (95% CI 25,918–26,152), and 795 consenting patients without clinical AF were included in the cohort study after stratification by sex and age (49.2% females; mean age 74.7 years). Patients in the cohort study underwent three seven-day Holter ECGs in intervals of two months to screen for AF. Results In the source population, the estimated prevalence of clinical AF was 22.2% (95% CI 18.4–26.1), 23.8% for males (95% CI 20.9–26.6) and 19.8% for females (95% CI 17.3–22.4; p for difference between sexes, 0.004). There was a linear trend for an increase in the prevalence of clinical AF with increasing age, overall and in both sexes. In the cohort study, AF was newly diagnosed in 38 patients, for an estimated prevalence of screen-detected AF of 4.9% overall (95% CI 3.3–6.6), 5.5% in males (95% CI 3.2–7.8) and 4.0% in females (95% CI 2.0–6.0; p for difference between sexes, 0.041). The estimated prevalence of screen-detected AF in the source population was 3.8% overall, 4.2% in males and 3.2% in females. Conclusion In a large hospital-based patient population aged 65–84 years, the prevalence of clinical AF and of screen-detected AF was 22.2% and 3.8%, respectively, and significantly higher in …

Note d’enjeux Considérations clés pour l’introduction et la levée des mesures de santé publique dans les écoles maternelles, primaires, secondaires et postsecondaires

Authors

Susan Law,Peter Jüni

Published Date

2021/10/18

L’année scolaire 2021-2022 a déjà commencé. Les élèves, les enseignants et le personnel fréquentent les écoles maternelles, primaires, secondaires et postsecondaires du Canada pour un apprentissage en présentiel.

Design considerations for overdose education and Naloxone distribution: Results of a multi-stakeholder workshop

Authors

Katherine Sellen,Benjamin Markowitz,Nick Goso,Alison Mulvale,Richard Hunt,Curtis Handford,Michelle Klaiman,Amy Wright,Mercy Charles,Ruby Sniderman,Peter Jüni,Laurie Morrison,Douglas Campbell,Pamela Leece,Carol Strike,Janet Parsons,Aaron Orkin

Published Date

2021/11/15

BackgroundOpioid overdose epidemic is a public health crisis that is impacting communities around the world. Overdose education and naloxone distribution programs equip and train lay people to respond in the event of an overdose. We aimed to design an open-access naloxone kit and ultra-brief education session for use in point-of-care settings.MethodsWe hosted a multi-stakeholder co-design workshop to elicit suggestions for the kit and education session. We recruited people with lived experience of opioid overdose, community representatives, and other stakeholders from family practice, emergency medicine, addictions medicine, and public health to participate in a one-day facilitated co-design discussion wherein large and small group discussions were audio-recorded, transcribed and analysed using thematic approaches.ResultsA total of twenty four participants participated in the multi-stakeholder workshop from five stakeholder groups including geographic and setting diversity. Collaborative dialogue and shared storytelling which revealed seven design considerations: recognizing overdose, how much naloxone, impact of stigma, legal risk of responding, position as conventional first aid, friends and family as responders, support to call 911.ConclusionTo create an open access kit and ultra-brief education session for distribution in emergency departments, family practice and substance use treatment services, stigma is a central design consideration. Design choices that reference the iconography, type, and form of materials associated with first aid have the potential to satisfy the need to de-stigmatize overdose response.

Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic …

Authors

Michelle Sholzberg,Grace H Tang,Elnara Negri,Hassan Rahhal,Lisa Baumann Kreuziger,Carlos E Pompilio,Paula James,Michael Fralick,Musaad AlHamzah,Faris Alomran,Eric Tseng,Gloria Lim,David Lillicrap,Marc Carrier,Fionnuala Ní Áinle,Andrew Beckett,Bruno R da Costa,Kevin Thorpe,Saskia Middeldorp,Agnes Lee,Mary Cushman,Peter Jüni

Journal

Trials

Published Date

2021/12

Objectives To determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to standard care in hospitalized patients admitted for COVID-19 with an elevated D-dimer on the composite outcome of intensive care unit (ICU) admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death up to 28 days. Trial design Open-label, parallel, 1:1, phase 3, 2-arm randomized controlled trial Participants The study population includes hospitalized adults admitted for COVID-19 prior to the development of critical illness. Excluded individuals are those where the bleeding risk or risk of transfusion would generally be considered unacceptable, those already therapeutically anticoagulated and those who have …

Effect of continuous electrocardiogram monitoring on detection of undiagnosed atrial fibrillation after hospitalization for cardiac surgery: a randomized clinical trial

Authors

Andrew CT Ha,Subodh Verma,C David Mazer,Adrian Quan,Bobby Yanagawa,David A Latter,Terrence M Yau,Frédéric Jacques,Craig D Brown,Rohit K Singal,Michael H Yamashita,Tarit Saha,Kevin H Teoh,Buu-Khanh Lam,Marc W Deyell,Marnee Wilson,Makoto Hibino,Christopher C Cheung,Andrew Kosmopoulos,Vinay Garg,Shira Brodutch,Hwee Teoh,Fei Zuo,Kevin E Thorpe,Peter Jüni,Deepak L Bhatt,Atul Verma,Tahit Saha,SEARCH AF CardioLink-1 Investigators

Journal

JAMA network open

Published Date

2021/8/2

ImportancePostoperative atrial fibrillation (POAF) occurring after cardiac surgery is associated with adverse outcomes. Whether POAF persists beyond discharge is not well defined.ObjectiveTo determine whether continuous cardiac rhythm monitoring enhances detection of POAF among cardiac surgical patients during the first 30 days after hospital discharge compared with usual care.Design, Setting, and ParticipantsThis study is an investigator-initiated, open-label, multicenter, randomized clinical trial conducted at 10 Canadian centers. Enrollment spanned from March 2017 to March 2020, with follow-up through September 11, 2020. As a result of the COVID-19 pandemic, enrollment stopped on July 17, 2020, at which point 85% of the proposed sample size was enrolled. Cardiac surgical patients with CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, prior stroke or transient …

Corrigendum to “Mixed methods feasibility study for the surviving opioid overdose with naloxone education and resuscitation (SOONER) trial”[Resuscitation Plus 6 (2021) 100131]

Authors

Aaron M Orkin,Mercy Charles,Kristine Norris,Rekha Thomas,Leigh Chapman,Amy Wright,Douglas M Campbell,Curtis Handford,Michelle Klaiman,Shaun Hopkins,Rita Shahin,Kevin Thorpe,Peter Juni,Janet Parsons,Kate Sellen,Nick Goso,Richard Hunt,Pamela Leece,Laurie J Morrison,Vicky Stergiopoulos,Suzanne Turner,Carol Strike

Journal

Resuscitation Plus

Published Date

2021/9

The authors regret to inform that we have identified a computational error in our recent publication,“Mixed methods feasibility study for the Surviving Opioid Overdose with Naloxone Education and Resuscitation (SOONER) Trial”. This error was identified in the process of preparing another manuscript arising from the same study, which used similar statistical coding. In brief, our statistical team identified that there was a coding error in R involving the labelling of categorical variables. The issue has now been corrected.Our clinical trials unit has responded to this error by initiating a thorough investigation and quality assurance process including a root-cause analysis to determine how this occurred and ensure that this kind of error does not recur. In addition, all other analyses and reported statistics in this paper have been reviewed by an independent senior statistician to ensure that they are correct. The error identified affects Table 2 and Table 3 of the published manuscript. Revised versions of these tables are appended below. The authors would like to apologise for any inconvenience caused.

External validation of the GRACE risk score 2.0 in the contemporary all‐comers GLOBAL LEADERS trial

Authors

Masafumi Ono,Hideyuki Kawashima,Hironori Hara,Amr Gamal,Rutao Wang,Chao Gao,Neil O'Leary,Osama Soliman,Jan J Piek,Robert‐Jan van Geuns,Peter Jüni,Christian W Hamm,Marco Valgimigli,Pascal Vranckx,Stephan Windecker,Philippe Gabriel Steg,Keith AA Fox,Yoshinobu Onuma,Patrick W Serruys

Journal

Catheterization and cardiovascular interventions

Published Date

2021/10

Objectives This study aimed to assess the predictive ability of the Global Registry of Acute Coronary Events (GRACE) risk score 2.0 in contemporary acute coronary syndrome (ACS) patients, and its relation to antiplatelet strategies. Background The predictive value of the GRACE risk score in the contemporary ACS cohort and the appropriate antiplatelet regimen according to the risk remain unclear. Methods This is a subgroup analysis of the all‐comers, randomized GLOBAL LEADERS trial, comparing ticagrelor monotherapy versus conventional dual‐antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). The GRACE risk score 2.0 with 1‐year mortality prediction was implemented. The randomized antiplatelet effect was assessed in predefined three GRACE risk‐groups; low‐risk (GRACE <109), moderate‐risk (GRACE 109–140), and high‐risk (GRACE >140). Results The GRACE risk score …

COVID-19 Infection Prevention and Control (IPAC) in Long-Term Care Facilities in two OECD countries, the Netherlands and Denmark: Best Practices, Implementation, Compliance

Authors

Peter Jüni,Susan Law

Published Date

2021/10/19

This Issue Note summarizes our understanding of ‘best practices’ for COVID-19 infection prevention and control (IPAC) in long-term care facilities (LTCFs) in two OECD countries recognized as high performing in this area—the Netherlands and Denmark.Our analysis led us to an inclusive definition of IPAC measures. We considered policies, procedures, and practices in the health, social, and long-term care system that impact the prevention of infections in LTCFs (not merely the IPAC practices typically considered by the clinical/medical discipline of infectious disease control). In that sense, we considered IPAC more as a concept than as a particular set of predefined clinical practices. We describe how these systemic ‘best practices’ in IPAC were implemented in the first place (ie supports, tools, policies that enabled adoption), and how ongoing compliance over time was enabled. Considerations for Canada draw from both the published literature and from our expert consultations.

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 …

Authors

Michelle Sholzberg,Grace H Tang,Hassan Rahhal,Musaad AlHamzah,Lisa Baumann Kreuziger,Fionnuala Ní Áinle,Faris Alomran,Khalid Alayed,Mohammed Alsheef,Fahad AlSumait,Carlos Eduardo Pompilio,Catherine Sperlich,Sabrena Tangri,Terence Tang,Peter Jaksa,Deepa Suryanarayan,Mozah Almarshoodi,Lana A Castellucci,Paula D James,David Lillicrap,Marc Carrier,Andrew Beckett,Christos Colovos,Jai Jayakar,Marie-Pier Arsenault,Cynthia Wu,Karine Doyon,E Roseann Andreou,Vera Dounaevskaia,Eric K Tseng,Gloria Lim,Michael Fralick,Saskia Middeldorp,Agnes YY Lee,Fei Zuo,Bruno R Da Costa,Kevin E Thorpe,Elnara Márcia Negri,Mary Cushman,Peter Jüni

Journal

bmj

Published Date

2021/10/14

Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards.Design Randomised controlled, adaptive, open label clinical trial.Setting 28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and US.Participants 465 adults admitted to hospital wards with covid-19 and increased D-dimer levels were recruited between 29 May 2020 and 12 April 2021 and were randomly assigned to therapeutic dose heparin (n=228) or prophylactic dose heparin (n=237).Interventions Therapeutic dose or prophylactic dose heparin (low molecular weight or unfractionated heparin), to be continued until hospital discharge, day 28, or death.Main outcome measures The primary outcome was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or admission to an intensive care …

TCT-201 Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention

Authors

Masafumi Ono,Yoshinobu Onuma,Hideyuki Kawashima,Hironori Hara,Chao Gao,Rutao Wang,Neil O’Leary,Scot Garg,Peter Juni,Christian Hamm,Marco Valgimigli,Stephan Windecker,Pascal Vranckx,Efthymios Deliargyris,Deepak Bhatt,Robert Storey,Patrick Serruys

Journal

Journal of the American College of Cardiology

Published Date

2021/11/9

BackgroundSeveral studies have suggested that proton pump inhibitors (PPIs) may reduce the antiplatelet effects of clopidogrel and/or aspirin, possibly leading to cardiovascular events.MethodsThis is a subanalysis of the randomized GLOBAL LEADERS trial, comparing the experimental antiplatelet arm (23-month ticagrelor monotherapy after 1-month dual anti-platelet therapy [DAPT]) with the reference arm (12-month aspirin monotherapy after 12-month DAPT) after percutaneous coronary intervention. Patient-oriented composite end points (POCE: all-cause mortality, myocardial infarction, stroke, and repeat revascularization) and its components were assessed stratified by PPI use as a time-dependent covariate in patients in the experimental and reference antiplatelet arms.ResultsAmong 15,839 patients, 2,115 (13.5%) had experienced POCE at 2 years. In the reference arm, the use of PPIs was independently …

Predicting 2‐year all‐cause mortality after contemporary PCI: updating the logistic clinical SYNTAX score

Authors

Ply Chichareon,David van Klaveren,Rodrigo Modolo,Norihiro Kogame,Kuniaki Takahashi,Chun‐Chin Chang,Mariusz Tomaniak,Jinqing Yuan,Lihua Xie,Ying Song,Shubin Qiao,Yuejin Yang,Changdong Guan,Aleksander Zurakowski,Robert‐Jan van Geuns,Manel Sabate,Paul J Ong,Joanna J Wykrzykowska,Jan J Piek,Scot Garg,Christian Hamm,Gabriel Steg,Pascal Vranckx,Marco Valgimigli,Stephan Windecker,Peter Juni,Yoshinobu Onuma,Ewout Steyerberg,Bo Xu,Patrick W Serruys

Journal

Catheterization and cardiovascular interventions

Published Date

2021/12/1

Aims We aimed to update the logistic clinical SYNTAX score to predict 2 year all‐cause mortality after contemporary percutaneous coronary intervention (PCI). Methods and results We analyzed 15,883 patients in the GLOBAL LEADERS study who underwent PCI. The logistic clinical SYNTAX model was updated after imputing missing values by refitting the original model (refitted original model) and fitting an extended new model (new model, with, selection based on the Akaike Information Criterion). External validation was performed in 10,100 patients having PCI at Fu Wai hospital. Chronic obstructive pulmonary disease, prior stroke, current smoker, hemoglobin level, and white blood cell count were identified as additional independent predictors of 2 year all‐cause mortality and included into the new model. The c‐indexes of the original, refitted original and the new model in the derivation cohort were 0.74 (95 …

Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke

Authors

David M Kent,Jeffrey L Saver,Scott E Kasner,Jason Nelson,John D Carroll,Gilles Chatellier,Geneviève Derumeaux,Anthony J Furlan,Howard C Herrmann,Peter Jüni,Jong S Kim,Benjamin Koethe,Pil Hyung Lee,Benedicte Lefebvre,Heinrich P Mattle,Bernhard Meier,Mark Reisman,Richard W Smalling,Lars Soendergaard,Jae-Kwan Song,Jean-Louis Mas,David E Thaler

Journal

Jama

Published Date

2021/12/14

ImportancePatent foramen ovale (PFO)–associated strokes comprise approximately 10% of ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke recurrence risk overall, the best treatment for any individual is often unclear.ObjectiveTo evaluate heterogeneity of treatment effect of PFO closure on stroke recurrence based on previously developed scoring systems.Design, Setting, and ParticipantsInvestigators for the Systematic, Collaborative, PFO Closure Evaluation (SCOPE) Consortium pooled individual patient data from all 6 randomized clinical trials that compared PFO closure plus medical therapy vs medical therapy alone in patients with PFO-associated stroke, and included a total of 3740 participants. The trials were conducted worldwide from 2000 to 2017.ExposuresPFO closure plus medical therapy vs medical therapy alone. Subgroup analyses used the Risk of Paradoxical …

Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near …

Authors

Christian Zanchin,Konstantinos C Koskinas,Yasushi Ueki,Sylvain Losdat,Jonas D Haener,Sarah Bär,Tatsuhiko Otsuka,Andrea Inderkum,Maria Radu Juul Jensen,Jacob Lonborg,Gregor Fahrni,Anna S Ondracek,Joost Daemen,Robert-Jan van Geuns,Juan F Iglesias,Christian M Matter,David Spirk,Peter Juni,Francois Mach,Dik Heg,Thomas Engstrom,Irene Lang,Stephan Windecker,Lorenz Raeber

Journal

American heart journal

Published Date

2021/8/1

BackgroundThe risk for cardiovascular adverse events after acute myocardial infarction (AMI) remains high despite potent medical treatment including low-density lipoprotein cholesterol (LDL-C) lowering with statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies substantially reduce LDL-C when added to statin. Alirocumab, a monoclonal antibody to PCSK9, reduces major adverse cardiovascular events after AMI. The effects of alirocumab on coronary atherosclerosis including plaque burden, plaque composition and fibrous cap thickness in patients presenting with AMI remains unknown.AimsTo determine the effect of LDL-C lowering with alirocumab on top of high-intensity statin therapy on intravascular ultrasound (IVUS)-derived percent atheroma volume (PAV), near-infrared spectroscopy (NIRS)-derived maximum lipid core burden index within 4 mm (maxLCBI4 mm) and optical coherence …

‘Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI’: a post hoc analysis of the randomized …

Authors

Amr S Gamal,Hironori Hara,Mariusz Tomaniak,Mattia Lunardi,Chao Gao,Masafumi Ono,Hideyuki Kawashima,Peter Jüni,Pascal Vranckx,Stephan Windecker,Christian Hamm,Philippe Gabriel Steg,Yoshinobu Onuma,Patrick W Serruys

Journal

European Heart Journal Acute Cardiovascular Care

Published Date

2021/9/1

Aim To evaluate the efficacy and safety of ticagrelor monotherapy beyond 1 month and up to 24 months vs. standard 12-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor followed by aspirin monotherapy among ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) in the GLOBAL LEADERS trial. Methods and results We performed a post hoc analysis of STEMI patients in the GLOBAL LEADERS trial comparing experimental ticagrelor monotherapy (1062 patients) with standard 12-month DAPT (1030 patients). We evaluated predefined primary and secondary endpoints in both treatment arms. Rates of net adverse clinical events (NACE), patient-oriented composite endpoints (POCE), and bleeding academic research consortium (BARC)-defined bleeding Type 3 or 5 were also evaluated. At 2 years, there were …

Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre‐specified analysis of the GLOBAL LEADERS Trial

Authors

Pascal Vranckx,Marco Valgimigli,Ayodele Odutayo,Patrick W Serruys,Christian Hamm,Philippe Gabriel Steg,Dik Heg,Eugene P Mc Fadden,Yoshinobu Onuma,Edouard Benit,Luc Janssens,Roberto Diletti,Maurizio Ferrario,Kurt Huber,Lorenz Räber,Stephan Windecker,Peter Jüni,GLOBAL LEADERS Investigators

Journal

Journal of the American Heart Association

Published Date

2021/9/21

Background The optimal duration of dual antiplatelet therapy after coronary drug‐eluting stent placement in adults with stable coronary artery disease (SCAD) versus acute coronary syndromes (ACS) remains uncertain. Methods and Results This was a prespecified subgroup analysis of the GLOBAL LEADERS trial. Participants were randomly assigned 1:1 to the experimental or reference strategy, stratified by ACS (experimental, n=3750; reference, n=3737) versus SCAD (experimental, n=4230; reference, n=4251). The experimental strategy was 75 to 100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy. The reference strategy was 75 to 100 mg aspirin daily plus either 75 mg clopidogrel daily (for SCAD) or 90 mg ticagrelor twice daily (for ACS) for 12 months, followed by aspirin monotherapy for 12 months. The primary end point at 2 years was a …

Prévention et contrôle des infections (PCI) par la COVID-19 dans les établissements de soins de longue durée dans deux pays de l’OCDE, les Pays-Bas et le Danemark: Meilleures …

Authors

Nathan M Carbone,Peter Jüni,Susan Law

Published Date

2021/10/19

Cette note d’enjeux décrit 1) les «meilleures pratiques» en matière de prévention et de contrôle des infections (PCI) dans les établissements de soins de longue durée (ÉSLD) dans certains pays de l’OCDE; 2) les mesures de soutien qui permettent l’adoption des meilleures pratiques; 3) les étapes qui favorisent la conformité continue aux meilleures pratiques au fil du temps; et 4) les points à considérer pour le Canada.Notre analyse nous a conduits à une définition inclusive des mesures de PCI. Nous avons pris en compte les politiques, les procédures et les pratiques du système de santé, du système social et du système de soins de longue durée qui contribuent à prévenir les infections dans les établissements de soins de longue durée (plutôt que les seules pratiques de PCI généralement prises en compte par la discipline clinique/médicale du contrôle des maladies infectieuses). Nous décrivons comment ces «meilleures pratiques» de conception de systèmes de soins intensifs de prévention des infections ont été mises en œuvre en premier lieu (c’est-à-dire les soutiens, les outils et les politiques qui ont permis leur adoption) et comment la conformité continue au fil du temps a été rendue possible.

Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis

Authors

Bruno R Da Costa,Tiago V Pereira,Pakeezah Saadat,Martina Rudnicki,Samir M Iskander,Nicolas S Bodmer,Pavlos Bobos,Li Gao,Henry Dan Kiyomoto,Thais Montezuma,Matheus O Almeida,Pai-Shan Cheng,Cesar A Hincapié,Roman Hari,Alex J Sutton,Peter Tugwell,Gillian A Hawker,Peter Jüni

Journal

bmj

Published Date

2021/10/12

Objective To assess the effectiveness and safety of different preparations and doses of non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and paracetamol for knee and hip osteoarthritis pain and physical function to enable effective and safe use of these drugs at their lowest possible dose.Design Systematic review and network meta-analysis of randomised trials.Data sources Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, regulatory agency websites, and ClinicalTrials.gov from inception to 28 June 2021.Eligibility criteria for selecting studies Randomised trials published in English with ≥100 patients per group that evaluated NSAIDs, opioids, or paracetamol (acetaminophen) to treat osteoarthritis.Outcomes and measures The prespecified primary outcome was pain. Physical function and safety outcomes were also assessed.Review methods Two reviewers independently …

See List of Professors in Peter Jüni University(University of Toronto)

Peter Jüni FAQs

What is Peter Jüni's h-index at University of Toronto?

The h-index of Peter Jüni has been 114 since 2020 and 158 in total.

What are Peter Jüni's top articles?

The articles with the titles of

The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials

Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of …

Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis: a network meta-analysis of large randomized trials

Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial

2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of …

Swiss trial of decompressive craniectomy versus best medical treatment of spontaneous supratentorial intracerebral haemorrhage (SWITCH): an international, multicentre …

Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through …

...

are the top articles of Peter Jüni at University of Toronto.

What are Peter Jüni's research interests?

The research interests of Peter Jüni are: Clinical Epidemiology, Epidemiology, Cardiology, Clinical Trials, Meta-Analysis

What is Peter Jüni's total number of citations?

Peter Jüni has 250,578 citations in total.

What are the co-authors of Peter Jüni?

The co-authors of Peter Jüni are Douglas G Altman, Matthias Egger, Prof Julian Higgins, David Moher, Jonathan Sterne.

    Co-Authors

    H-index: 281
    Douglas G Altman

    Douglas G Altman

    University of Oxford

    H-index: 183
    Matthias Egger

    Matthias Egger

    Universität Bern

    H-index: 183
    Prof Julian Higgins

    Prof Julian Higgins

    University of Bristol

    H-index: 182
    David Moher

    David Moher

    Ottawa University

    H-index: 147
    Jonathan Sterne

    Jonathan Sterne

    University of Bristol

    academic-engine

    Useful Links